Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 19494. Отображено 100.
16-02-2012 дата публикации

Novel Methods for Regeneration of Solvents for Extractive Processes

Номер: US20120037542A1
Принадлежит: AMT International Inc, CPC Corp Taiwan

An improved solvent regeneration system for extractive distillation and liquid-liquid extraction processes capable of effectively removing heavy hydrocarbons and polymeric materials that otherwise develop in a closed solvent loop. The improved process employs a light hydrocarbon displacement agent, which is at least partially soluble in the solvent to squeeze the heavy hydrocarbons and polymeric materials out of the solvent, with virtually no additional energy requirement. It has been demonstrated that the light non-aromatic hydrocarbons in the raffinate stream generated from the extractive distillation or the liquid-liquid extractive process for aromatic hydrocarbons recovery can displace not only the heavy non-aromatic hydrocarbons but also the heavy aromatic hydrocarbons from the extractive solvent, especially when the aromatic hydrocarbons in the solvent are in the C 10+ molecular weight range.

Подробнее
23-02-2012 дата публикации

Developers and method of coloring lithographic printing members

Номер: US20120045720A1
Принадлежит: Individual

A color contrast image in imaged lithographic printing precursors can be obtained by contacting the imaged precursor with a coloration solution containing a colorless form of a photochromic compound. Residual amounts of this compound attached to the oleophilic surface of the imaged precursor can be changed to its colored form when exposed to UV light. The coloration solution can be an alkaline or acidic developer or an alkaline or acidic solution used separately after development. The coloration solution can also be a gum solution.

Подробнее
19-04-2012 дата публикации

Organic Compounds Having Cooling Properties

Номер: US20120095042A1
Автор: Stefan Michael Furrer
Принадлежит: Givaudan SA

Provided are compounds of formula (I) wherein m is 0, 1 or 2; R I is a mono- or bicyclic heterocyclic ring system including one, two or three heteroatoms selected from nitrogen, sulphur and oxygen; R 2 is selected from hydrogen, methyl and ethyl; I) R 3 is hydrogen, methyl, or ethyl; and R 4 and R 5 are independently selected from ethyl and isopropyl; and R 3 , R 4 and R 5 together have at least 6 carbon atoms: or II) any two or all of R 3 , R 4 and R 5 form together with the carbon atom to which they are attached 3-para-menthyl, bornyl, or adamantyl; having cooling properties, their use as cooling agent and compositions including them.

Подробнее
03-05-2012 дата публикации

Novel microbiocides

Номер: US20120108645A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.

Подробнее
17-05-2012 дата публикации

Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery

Номер: US20120122920A1

New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides libraries which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target.

Подробнее
17-05-2012 дата публикации

Process for the preparation of strontium ranelate

Номер: US20120123131A1
Принадлежит: Individual

The present invention relates to an improved process for the synthesis of strontium ranelate or hydrates thereof. More particularly, the present invention relates to an effective process for the preparation of a compound of formula III, which is a useful intermediate in the synthesis of strontium ranelate. wherein R 1 and R 2 represents substituted or unsubstituted linear or branched C 1 -C 6 alkyl group or C 3 -C 12 cyclic group.

Подробнее
07-06-2012 дата публикации

Method for synthesis of secondary alcohols

Номер: US20120142934A1
Принадлежит: National Tsing Hua University NTHU

A method for synthesis of secondary alcohols is provided for pharmaceutical secondary alcohol by addition of organoboronic acids with aldehydes in presence of the cobalt ion and bidentate ligands as the catalyst. In addition, an enantioselective synthesis method for secondary alcohols is also herein provided in the present invention. The present invention has advantages in using less expensive cobalt ion and commercially available chiral ligands as the catalyst, wide scope of organoboronic acids and aldehydes compatible with this catalytic reaction and achieving excellent yields and/or enantiomeric excess.

Подробнее
14-06-2012 дата публикации

Ruthenium (ii) catalysts for use in stereoselective cyclopropanations

Номер: US20120149906A1
Принадлежит: Vanda Pharmaceuticals Inc

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N′-bis(3,5-di-t-butyl-salicylidene) and RuCl 2 (p-cymene)] 2 .

Подробнее
14-06-2012 дата публикации

(e)-n-monoalkyl-3-oxo-3-(2-thienyl) propenamine and process for producing the same and process for producing (e,z)-n-monoalkyl-3-oxo-3-(2-thienyl) propenamine

Номер: US20120149917A1
Принадлежит: Sumitomo Seika Chemicals Co Ltd

The present invention provides a process for producing (E)-N-monoalkyl-3-oxo-3-(2-thienyl)propenamine represented by Formula (1); wherein R is a C 1-4 alkyl, the method comprising the steps of: maintaining a solution containing (Z)—N-monoalkyl-3-oxo-3-(2-thienyl)propenamine dissolved therein at 25° C. or below to deposit crystals and separating crystals having a particle diameter of 100 μm or less from the deposited crystals; and a process for producing (E,Z)—N-monoalkyl-3-oxo-3-(2-thienyl)propenamine comprising the steps of: reacting an alkali metal salt of β-oxo-β-(2-thienyl)propanal with a monoalkylamine compound; adding a water-insoluble organic solvent to the resulting reaction mixture; adding seed crystals containing (E)-N-monoalkyl-3-oxo-3-(2-thienyl)propenamine to an organic layer obtained by conducting separation; and keeping the resulting mixture at 25° C. or below.

Подробнее
05-07-2012 дата публикации

Second-order nonlinear optical compound and nonlinear optical element comprising the same

Номер: US20120172599A1
Принадлежит: Individual

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore. Solution: a chromophore comprising a donor structure D, a π-conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

Подробнее
19-07-2012 дата публикации

Stilbene Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device

Номер: US20120184755A1
Принадлежит: Semiconductor Energy Laboratory Co Ltd

An object is to provide a novel stilbene compound suitable for an organic EL light-emitting material. Provided is a novel stilbene compound represented by a general formula (G1) below. In the formula, Q 1 and Q 2 separately represent an oxygen atom or a sulfur atom; R 1 to R 9 and R 11 to R 17 separately represent any one of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group; α 1 to α 6 separately represent a substituted or unsubstituted phenylene group; Ar 1 and Ar 2 separately represent any one of a substituted or unsubstituted aryl group having 6 to 12 carbon atoms forming a ring, a substituted or unsubstituted dibenzothiophen-2-yl group, and a substituted or unsubstituted dibenzofuran-2-yl group; and j, k, m, n, p, and q separately represent 0 or 1.

Подробнее
17-01-2013 дата публикации

Synthesis and applications of soluble pentacene precursors and related compounds

Номер: US20130017497A1
Принадлежит: Academia Sinica

The present disclosure relates to methods and systems for synthesis of bridged-hydropentacene, hydroanthracene and hydrotetracene from the precursor compounds pentacene derivatives, tetracene derivatives, and anthracene derivatives. The invention further relates to methods and systems for forming thin films for use in electrically conductive assemblies, such as semiconductors or photovoltaic devices.

Подробнее
14-02-2013 дата публикации

Novel naphthothiophene compound and organic light-emitting device including the same

Номер: US20130037789A1
Принадлежит: Canon Inc

The present invention provides a novel naphthothiophene compound having a high lowest excited triplet level (T1).

Подробнее
21-03-2013 дата публикации

Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon

Номер: US20130071328A1
Принадлежит: UNIVERSITY OF SOUTHERN CALIFORNIA

This invention discloses a series of novel propynoic acid carbamoyl methyl-amides (PACMAs), methods for synthesizing the PACMAs and pharmaceutical compositions containing the PACMAs. These novel compounds and compositions show cytotoxicity in cancer cells and are useful as lead compounds for anti-cancer drugs or pharmaceutical agents. This invention also discloses treatment methods that uses the PACMAs and pharmaceutical compositions as well as methods for promoting the release and nuclear localization of the transcription factor Nrf2. 4. A compound according to claim 1 , wherein said compound further contains a substituent capable of being used in a biological or medical diagnostic imagining technique to quantify or identify associated biomarker proteins.5. A compound according to claim 3 , wherein said compound further contains a substituent capable of being used in a biological or medical diagnostic imagining technique to quantify or identify associated biomarker proteins.7. A pharmaceutical composition comprising any of the compounds of to and a pharmaceutically acceptable carrier.8. A method for treatment a cancer subject claim 3 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'administering to a person in need of said treatment method an effective amount of the pharmaceutical composition according to .'}9. A method of claim 8 , where the cancer is: breast cancer claim 8 , ovarian cancer claim 8 , prostate cancer claim 8 , colon cancer claim 8 , brain cancer claim 8 , pancreatic cancer claim 8 , skin cancer claim 8 , lung cancer claim 8 , and multiple myeloma.10. A method for promoting the release and nuclear localization of the transcription factor Nrf2 comprising the step of:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'administering an effective amount of the pharmaceutical compositions according to .'}10. A biological or medical diagnostic imaging technique claim 8 , comprising:{'claim-ref': [{'@idref': 'CLM-00004', 'claims 4 ...

Подробнее
21-03-2013 дата публикации

COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS

Номер: US20130072473A1
Принадлежит:

The present invention is directed to compounds of Formulae (I), (IIa-IIh), (IIIa-IIIe), (IVa-IVc), (Va-V1), (VIa-VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis. 112-. (canceled)1427-. (canceled)28. The method of claim 13 , wherein Dis N(R) and wherein each Ris independently selected from the group consisting of hydrogen and optionally substituted C-Calkyl.2932-. (canceled)33. The method of claim 28 , wherein Gis an optionally substituted 5/6-membered fused heteroaryl.34. The method of claim 33 , wherein Gis benzothiazolyl claim 33 , benzoxazolyl claim 33 , benzimidazolyl claim 33 , benzothiophenyl claim 33 , and benzofuranyl claim 33 , each optionally substituted.3646-. (canceled)47. The method of claim 35 , wherein Gis an optionally substituted 5/6-membered fused heteroaryl.48. The method of claim 47 , wherein Gis benzothiazolyl claim 47 , benzoxazolyl claim 47 , benzimidazolyl claim 47 , benzothiophenyl claim 47 , and benzofuranyl claim 47 , each optionally substituted.5065-. (canceled)70. The method of claim 13 , wherein the condition is associated with a dysfunction in the proteostasis of a protein selected from the group consisting of hexosamine A claim 13 , cystic fibrosis transmembrane conductance regulator claim 13 , aspartylglucsaminidase claim 13 , a-galactosidase A claim 13 , cysteine transporter claim 13 , acid ceremidase claim 13 , acid α-L-fucosidase claim 13 , protective protein claim 13 , cathepsin A claim 13 , acid β-glucosidase claim 13 , acid β-galactosidase claim 13 , iduronate 2-sulfatase claim 13 , α-L-iduronidase claim 13 , galactocerebrosidase claim 13 , acid α-mannosidase claim 13 , acid β-mannosidase claim 13 , arylsulfatase B claim 13 , arylsulfatase A claim 13 , N-acetylgalactosamine-6-sulfate sulfatase claim 13 , acid β-galactosidase claim 13 , N-acetylglucosamine-1-phosphotransferase claim 13 , acid sphingmyelinase ...

Подробнее
28-03-2013 дата публикации

6,13-DIHALOGEN-5,14-DIHYDROPENTACENE DERIVATIVE AND METHOD FOR PRODUCING 6,13-SUBSTITUTED-5,14-DIHYDROPENTACENE DERIVATIVE USING SAME

Номер: US20130079530A1
Принадлежит:

The present invention provides a 6,13-dihalogen-5,14-dihydropentacene derivative and a method for production thereof. Compounds (b) and (c) are reacted through cross-coupling reaction in the presence of a metal compound and a lithiating agent to synthesize compound (d), which is then halogenated to thereby obtain a 6,13-dihalogen-5,14-dihydropentacene derivative (compound (e)). 2. The derivative according to claim 1 , wherein Xand Xare each an iodine atom.3. The derivative according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand R claim 1 , which may be the same or different claim 1 , are each independently a hydrogen atom; an optionally substituted C-Calkyl group; an optionally substituted C-Caryl group or an optionally substituted silyl group.4. The derivative according to any claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rare each a hydrogen atom.6. The method according to claim 5 , wherein the organometallic compound is selected from the group consisting of an organolithium compound claim 5 , an organomagnesium compound claim 5 , an organoaluminum compound claim 5 , an organozinc compound claim 5 , an organoboron compound and an organosilyl compound.8. The method according to any claim 5 , wherein the transition metal catalyst comprises a nickel complex or a palladium complex.9. The method according to claim 5 , wherein Aand A claim 5 , which may be the same or different claim 5 , are each independently an optionally substituted C-Calkyl group claim 5 , an optionally substituted C-Calkenyl group claim 5 , an optionally substituted C-Calkynyl group claim 5 , an optionally substituted C-Caryl group or an optionally substituted heteroaryl group.10. The method according to claim 5 , wherein Xand Xare each an iodine atom.11. The method according to claim 5 , wherein R claim 5 , R claim 5 , R claim 5 , R claim 5 , R claim ...

Подробнее
18-04-2013 дата публикации

COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Номер: US20130096106A1

Compounds represented by formula: 3. A compound according to claim 1 , wherein Z is 6-7 membered heterocycle or 6-7 membered cycloalkyl.4. A compound according to claim 1 , wherein Z is cyclohexyl claim 1 , piperidinyl claim 1 , N—(Calkyl)-piperidinyl claim 1 , hexahydrothiopyranyl claim 1 , azepanyl claim 1 , methylazepanyl claim 1 , N—(Calkyl)-piperidinylmethyl claim 1 , tetrahydropyranyl claim 1 , piperidinylmethyl claim 1 , pyridinyl claim 1 , pyridinylmethyl claim 1 , tetrahydrothiopyranyl claim 1 , dioxolanylmethyl or dioxanylmethyl which in each case is unsubstituted or substituted by one or more substituent chosen from halogen claim 1 , nitro claim 1 , nitroso claim 1 , SORf claim 1 , SORf claim 1 , PORcRd claim 1 , CONRgRh claim 1 , Calkyl claim 1 , Calkenyl claim 1 , Calkynyl claim 1 , Caralkyl claim 1 , Caryl claim 1 , Calkyloxy claim 1 , Calkenyloxy claim 1 , Calkynyloxy claim 1 , Caryloxy claim 1 , C(O)Calkyl claim 1 , C(O)Calkenyl claim 1 , C(O)Calkynyl claim 1 , C(O)Caryl claim 1 , C(O)Caralkyl claim 1 , C(O)NHRf claim 1 , Cheterocycle claim 1 , hydroxyl claim 1 , NRgRh claim 1 , C(O)ORf claim 1 , cyano claim 1 , azido claim 1 , amidino or guanido;{'sub': 1-6', '2-6', '2-6', '6-10', '3-10', '3-10', '6-10, 'wherein Rf, Rc, Rd, Rg and Rh in each case is H, Calkyl, Calkenyl, Calkynyl, Caryl, Cheterocycle, Cheteroaralkyl or Caralkyl;'}or Rc and Rd are taken together with the oxygens to form a 5 to 10 membered heterocycle;or Rg and Rh are taken together with the nitrogen to form a 3 to 10 membered heterocycle.5. A compound according to claim 1 , wherein Z is cyclohexyl unsubstituted or substituted by one or more substituent chosen from halogen claim 1 , SORf claim 1 , CONRgRh claim 1 , Calkyl claim 1 , Caralkyl claim 1 , Caryl claim 1 , Calkyloxy claim 1 , C(O)Calkyl claim 1 , Cheterocycle claim 1 , hydroxyl claim 1 , NRgRh claim 1 , C(O)Orf or cyano;{'sub': '1-6', 'wherein Rf, Rg and Rh in each case is H or Calkyl.'}6. A compound according to claim 1 , ...

Подробнее
18-04-2013 дата публикации

Process for preparing optically active antrocin

Номер: US20130096324A1
Принадлежит: Deyew Biotech Corp

The present invention relates to a process of preparation of optically active antrocin. At first, to introduce the correct configuration of trans-decalone, alkyl aluminum/TMSCN was used to react with decalenone. The resulting racemic nitrile-decalone was resolved with chiral diol by ketalization to produce two chromatography separable diasteromers. After a simple column chromatography, optically pure compounds were obtained. Formylation was a critical step for the lactone formation. The rest of the synthesis is straight forward through oxidation and olefination. Accordingly, the total synthesis was completed in 10 steps with 7% overall yield from commercially available 6-methoxy-2-tetralone.

Подробнее
25-04-2013 дата публикации

ANTIMICROBIAL COMPOUNDS OF 1,4-NAPHTOQUINONE STRUCTURE

Номер: US20130102650A1
Принадлежит:

The present invention relates to a compound having formula (I) wherein: Ris chosen from the group consisting of: phenyl group, possibly substituted, —CH—CH—R′group, R′being chosen from the group consisting of: H, —OH, halogen, alkyl, aryl, CHO, —CN, —NO, —SR, —OR, —NRR, —CONRR, —COOR, and —NHCOR, Rand Rrepresenting independently from each other H, an alkyl group or an aryl group, R′being preferably in para position, and —CH—CO—R′ group, R′ representing an aryl or heteroaryl group, said aryl and heteroaryl groups being possibly substituted, Ris chosen from the group consisting of: —OH and halogen, and R, R, Rand Rare in particular H, for its use for the prevention and/or the treatment of bacterial infections. 3. The compound according to claim 1 , wherein Ris a substituted or unsubstituted phenyl group.4. The compound according to claim 1 , wherein Ris a phenyl group claim 1 , substituted by an aryl group.5. The compound according to claim 1 , wherein Ris chosen from the group consisting of: —CH—CH—R′group and —CH—CO—R′ group claim 1 , R′and R′ being as defined in .7. The compound according to claim 6 , wherein R′is a group in para position having formula —OR′ claim 6 , R′being H or an alkyl group comprising from 1 to 6 carbon atoms.8. The compound according to claim 6 , wherein Ris chosen from the groups having formula —CH—CO—R′ claim 6 , R′ being as defined in .9. The compound according to claim 8 , wherein R′ is a substituted and unsubstituted aryl group.10. The compound for the use according to claim 8 , wherein R′ is a substituted or unsubstituted phenyl group.12. The compound according to claim 11 , wherein R′is a group in para position chosen from the alkyl groups comprising from 1 to 6 carbon atoms claim 11 , and the groups having formula —OR′ claim 11 , R′being chosen from H and alkyl groups comprising from 1 to 6 carbon atoms.13. The compound according to claim 1 , wherein R′ is a substituted and unsubstituted heteroaryl group.15. (canceled)16. The ...

Подробнее
25-04-2013 дата публикации

Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives

Номер: US20130102794A1
Принадлежит: UCB PHARMA GMBH

The present invention provides an alternative synthesis of N-substituted aminotetralines comprising resolution of N-substituted aminotetralins of formula (II), wherein R 1 , R 2 and R 3 are as defined for compound of formula (I).

Подробнее
16-05-2013 дата публикации

Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound

Номер: US20130119355A1
Принадлежит: Samsung Display Co Ltd

A styryl-based compound represented by Formula 1, a composition containing the styryl-based compound, and an organic light-emitting diode (OLED) including the styryl-based compound: The styryl-based compound may exhibit high heat resistance and thus an OLED including the same may have low driving voltage, high brightness, high efficiency, and long lifetime.

Подробнее
16-05-2013 дата публикации

CARBOCATALYSTS FOR CHEMICAL TRANSFORMATIONS

Номер: US20130123514A1
Принадлежит: GRAPHEA, INC.

The disclosure relates to catalytically active carbocatalysts, e.g., a graphene oxide or graphite oxide catalyst suitable for use in a variety of chemical transformations. In one embodiment, it relates to a method of catalyzing a chemical reaction of an organic molecule by reacting the organic molecule in the presence of a sufficient amount of graphene oxide or graphite oxide for a time and at a temperature sufficient to allow catalysis of a chemical reaction. According to other embodiments, the reaction may be an oxidation reaction, a hydration reaction, a dehydrogenation reaction, a condensation reaction, or a polymerization reaction. Some reactions may include auto-tandem reactions. The disclosure further provides reaction mixtures containing an organic molecule and graphene oxide or graphite oxide in an amount sufficient to catalyze a reaction of the organic molecule. 1. A method for chemically transforming an organic compound , comprising:(a) contacting the organic compound with a catalytically active carbocatalyst having a surface terminated with one or more peroxide, hydroxyl, aldehyde, or carboxylic acid groups; and(b) transforming the organic compound with the aid of the catalytically active carbocatalyst to form a mixture of a reaction product and a spent or partially spent carbocatalyst.2. The method of claim 1 , wherein the catalytically active carbocatalyst is an oxidized form of graphite.3. The method of claim 2 , wherein the catalytically active carbocatalyst is graphene oxide or graphite oxide.4. The method of claim 1 , wherein the catalytically active carbocatalyst is an oxidized carbon-containing material.5. The method of claim 1 , wherein the catalytically active carbocatalyst is characterized by one or more FT-IR features at about 3150 cm claim 1 ,1685 cm claim 1 , 1280 cm claim 1 , or 1140 cm.629-. (canceled)30. The method of claim 1 , wherein the organic compound has at least one sp-hybridized C—H bond claim 1 , and the transformation involves ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS

Номер: US20130131340A1
Автор: Forman Barry, Yu Donna
Принадлежит:

Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described. 2. (canceled)3. The compound of wherein X is S claim 1 , and R is selected from the group consisting of 5-CHand 5-NO claim 1 , and wherein the compound is an estrogen-related receptor (ERR) agonist.4. The compound of wherein X is O claim 1 , and R is selected from the group consisting of 4 claim 1 ,5-CHand 5-CHCH claim 1 , andwherein the compound is an estrogen-related receptor (ERR) agonist.5. (canceled)6. (canceled)7. (canceled)11. The compound of claim 10 , wherein the compound is an ERRα/β/γ agonist.12. The compound of claim 10 , wherein the compound is an ERRβ/γ agonist.13. The compound of wherein the compound is an ERRγ agonist.16. The compound of claim 15 , wherein the compound is an ERRα/β/γ agonist.17. The compound of claim 15 , wherein the compound is an ERRβ/γ agonist.18. The compound of wherein the compound is an ERRγ agonist. This application is a divisional of U.S. patent application Ser. No. 12/475,323, filed May 29, 2009 and now pending, which is a divisional of U.S. patent application Ser. No. 11/336,515, filed Jan. 20, 2006 and issued as U.S. Pat. No. 7,544,838 on Jun. 9, 2009, which claims priority to U.S. Provisional Application No. 60/646,128, filed Jan. 21, 2005, all of which are incorporated herein by reference in their entirety.The present invention relates to ligands and methods for synthesis of said ligands.Metabolic disease, including obesity, diabetes and atherosclerosis, is the leading cause of mortality in industrialized nations. It is estimated that over one-third of the United States population is obese and these individuals are at risk for developing diabetes and atherosclerosis. These disorders are responsible for over 500,000 deaths in the United States each year. The growing incidence of this problem has led to intense interest in identifying new molecular targets and new pharmacologic agents to treat and/or prevent ...

Подробнее
23-05-2013 дата публикации

Novel Process for the Preparation of Dronedarone

Номер: US20130131358A1
Автор: FRIESZ Antal, HUSZAR Csaba
Принадлежит: SANOFI

The subject of the invention is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-di-n-butylamino)-propoxy]benzoyl}benzofuran-5-yl]-methanesulfonamide of formula I: 2. The process according to claim 1 , comprising carrying out the reaction in an alcoholic organic solvent or in a mixture of alcoholic organic solvents.3. The process according to claim 1 , comprising carrying out the reaction in the presence of an alkali alcoholate.4. The process according to claim 1 , comprising carrying out the reaction in the presence of an alkali metal- or alkali earth metal hydroxide.5. The process according to claim 1 , comprising carrying out the reaction in the presence of an inorganic acid.6. The process according to claim 1 , comprising carrying out the reaction at a temperature between 20° C. and the boiling point of the applied solvent or solvent mixture.8. The process according to claim 7 , comprising carrying out the reaction in step a) in an inert organic solvent or in a mixture of inert organic solvents.9. The process according to claim 7 , comprising carrying out the reaction in step a) in the presence of an acid binder.10. The process according to claim 7 , comprising carrying out the reaction in step b) in an inert organic solvent or in a mixture of inert organic solvents.12. The process according to claim 11 , comprising carrying out the reaction in step a) in an inert organic solvent or in a mixture of inert organic solvents.13. The process according to claim 11 , comprising carrying out the reaction in step a) in the presence of an acid binder.14. The process according to claim 11 , comprising carrying out the reaction in step b) an inert organic solvent or in a mixture of inert organic solvents. This application is a continuation of International Application No. PCT/HU2011//000067, filed Jul. 13, 2011, which is incorporated herein by reference, and which claims the benefit of priority of Hungarian Application No. P1000386, filed Jul. 22, 2010.This ...

Подробнее
06-06-2013 дата публикации

INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS

Номер: US20130143765A1

Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased chloride and fluid secretion, for example, secretory diarrhea. 425-. (canceled)27. The composition of wherein at least one of Rand Ris not hydrogen.29112.-. (canceled)113. An isolated epithelial cell comprising (i) a calcium-activated chloride channel and (ii) a recombinant cytoplasmic indicator protein that binds halide.114. The epithelial cell of wherein the epithelial cell is an intestinal epithelial cell or a pulmonary epithelial cell.115. The epithelial cell of wherein the intestinal epithelial cell is an HT-29 cell.116. The epithelial cell of wherein the cytoplasmic indicator protein is a yellow fluorescent protein (YFP) mutant.117. The epithelial cell of claim 116 , wherein the YFP mutant is YFP-H148Q/I152L.118. The epithelial cell of wherein the calcium-activated chloride channel is TMEM16A.119. The epithelial cell of wherein TMEM16A is human TMEM16A.120. The epithelial cell of wherein the recombinant cytoplasmic indicator protein is introduced into the cell by a recombinant expression vector that is a viral vector.121. The method of wherein the viral vector is a retroviral vector.122. The method of wherein the retroviral vector is a lentiviral vector.123. A method of identifying an agent that is an inhibitor of a calcium-activated chloride channel comprising:{'claim-ref': {'@idref': 'CLM-00113', 'claim 113'}, '(a) contacting the isolated epithelial cell of and a candidate agent in a test sample to permit interaction between the candidate agent and the cell;'}{'sup': '2', '(b) adding to the test sample (i) at least one ...

Подробнее
06-06-2013 дата публикации

NOVEL SEROTONIN REUPTAKE INHIBITORS AS DRUGS HAVING PERIPHERAL-SYSTEM-RESTRICTED ACTIVITY

Номер: US20130143960A1
Принадлежит: Ramot at Tel-Aviv University Ltd.

Serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation. 1. A serotonin reuptake inhibitor (SRI) compound , being modified so as to comprise at least one positively charged group , said at least one positively charged group being selected such that the modified SRI compound retains its charge at physiological pH , while substantially retaining its SRI activity.2. The SRI compound of claim 1 , wherein said positively charged group is a quaternary ammonium group.3. The SRI compound of claim 2 , wherein said quaternary ammonium group has the formula:{'br': None, 'sub': 1', '2', '3, 'sup': +', '−, '—(NRRR)Z'}wherein:Z is an organic or inorganic anion; and{'sub': 1', '2', '3, 'R, Rand Rare each independently selected from the group consisting of alkyl, aryl and cycloalkyl.'}4. The SRI compound of claim 3 , wherein R claim 3 , Rand Rare each independently an alkyl having from 1 to 4 carbon atoms.5. The SRI compound of claim 4 , wherein said alkyl is methyl.6. The SRI compound of claim 1 , wherein said positively charged group is a tertiary sulfonium group.7. The SRI compound of claim 1 , being derived from a compound selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI) claim 1 , a serotonin-norepinephrine reuptake inhibitor (SNRI) and a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI).8. The SRI compound of claim 7 , wherein said SSRI is selected from the group consisting of citalopram claim 7 , alaproclate claim 7 , dapoxetine claim 7 , etoperidone claim 7 , fluoxetine claim 7 , fluvoxamine claim 7 , paroxetine claim 7 , sertraline claim 7 , venlafaxine and zimelidine ...

Подробнее
20-06-2013 дата публикации

CALIXARENE COMPOUND AND PHOTORESIST COMPOSITION COMPRISING SAME

Номер: US20130157195A1
Принадлежит: Rohm and Haas Electronic Materials LLC

A molecular glass compound includes (A) a tetrameric reaction product of a specific aromatic compound having at least one hydroxy group, and a specific polycyclic or fused polycyclic aromatic aldehyde; and (B) an acid-removable protecting group as an adduct with the hydroxy group of the aromatic compound and/or a hydroxy group of the polycyclic or fused polycyclic aromatic aldehyde. A photoresist composition including the molecular glass compound, and a coated substrate including a layer of the photoresist composition are also disclosed. 2. The molecular glass compound of claim 1 , wherein the aromatic compound of formula (I) is resorcinol claim 1 , pyrogallol claim 1 , 3-methoxyphenol claim 1 , or 3-ethoxyphenol.3. The molecular glass compound of claim 1 , wherein Arof Formula (II) is a Caryl claim 1 , Cheteroaryl claim 1 , Chaloaryl claim 1 , Cheterohaloaryl claim 1 , Caralkyl claim 1 , or Chaloaralkyl.5. The molecular glass compound of claim 1 , wherein the acid-removable protecting group is the adduct of a vinyl ether claim 1 , a tertiary alkyl ester claim 1 , a tertiary alkyl carbonyl claim 1 , or a combination comprising at least one of the foregoing.7. A photoresist claim 1 , comprising the molecular glass compound of .8. A photoresist claim 1 , comprising the molecular glass compound of claim 1 , a solvent claim 1 , and a photoacid generator.9. A coated substrate claim 8 , comprising: (a) a substrate having one or more layers to be patterned on a surface thereof; and (b) a layer of a photoresist composition of over the one or more layers to be patterned.10. A method of forming a patterned substrate claim 9 , comprising exposing the coated substrate of to activating radiation.11. The method of claim 10 , wherein exposure is with e-beam and/or EUV radiation. This application is a nonprovisional filing of provisional application 61/538,672, filed Sep. 23, 2011, the content of which is incorporated herein by reference in its entirety.Design rules for advanced ...

Подробнее
20-06-2013 дата публикации

NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY

Номер: US20130157982A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. 2. A compound according to claim 1 , wherein:{'sup': 1', '10, 'Ris N or C—R;'}{'sup': '2', 'Ris optionally substituted aromatic heterocycle or optionally substituted cycloalkenyl;'}{'sup': 3', '11', '12', '13', '14, 'Ris O, N—R, CH—Ror S, —CR═CR—, —C(O) or —C≡C—;'}{'sup': '4', 'Ris H, optionally substituted aromatic heterocycle, optionally substituted non-aromatic heterocycle, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted aryl;'}{'sup': '5', 'sub': 1-3', '1-3, 'Ris H, halogen, hydroxyl, —OCalkyl, or Calkyl;'}{'sup': '6', 'sub': 1-3', '1-3, 'Ris H, Calkyl, halogen, hydroxyl or —OCalkyl;'}{'sup': '7', 'sub': '1-6', 'Ris H or Calkyl;'}{'sup': '8', 'sub': '1-6', 'Ris H or Calkyl;'}{'sup': 9', '15, 'sub': 3', '2', '2', '3-6', '2, 'Ris —OPOH, —COOH, —P(O)(OH), —Calkyl, —S(O)OH, —P(O)MeOH, —P(O)(H)OH or —OR;'}{'sup': '10', 'sub': 1-6', '1-3, 'Ris H, Calkyl, halogen, hydroxyl or —OCalkyl;'}{'sup': '11', 'sub': '1-3', 'Ris H or Calkyl;'}{'sup': '12', 'sub': 1-3', '1-3, 'Ris H, Calkyl, halogen, hydroxyl, —OCalkyl or amino;'}{'sup': '13', 'sub': '1-3', 'Ris H or Calkyl;'}{'sup': '14', 'sub': '1-3', 'Ris H or Calkyl;'}{'sup': '15', 'sub': '1-3', 'Ris H or Calkyl;'}{'sup': 16', '17, 'L is CHR, O, S, NRor —C(O)—;'}a is 0, 1, 2, 3, 4 or 5;b is 0, 1, 2, 3, 4 or 5;c is 0 or 1;d is 0, 1, 2 or 3;{'sup': '16', 'sub': 1-3', '1-3, 'Ris H, Calkyl, —OCalkyl, halogen, hydroxyl or amino, and'}{'sup': '17', 'sub': '1-3', 'Ris H or Calkyl;'}with the provisos:{'sup': 3', '11', '17, 'a). when Ris O, N—R, or S, and b is 0 or 1 then L is not O, S, or NR; and'}{'sup': '9', 'sub': 3', '2', '2', '2, 'b). when Ris —OPOH, —COOH, —P(O)(OH), —S(O)OH, —P(O)MeOH or —P(O)(H)OH'}then d is not 0; and{'sup': 9', '15, 'c). when Ris ORthen d is not ...

Подробнее
20-06-2013 дата публикации

METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES

Номер: US20130158017A1
Автор: Li Yueming, Zhu Lei

Provided are methods of treating or preventing a neurodegenerative disease comprising administering to a subject having a neurodegenerative disease an effective amount of a compound of Formula I: 218-. (canceled)21. (canceled)23. The method of claim 20 , wherein each Ris H.24. (canceled)25. The method of claim 20 , wherein v is 1 and X is in the 5-position of the thiopheno group.26. The method of claim 20 , wherein p is 1 and Ris in the 4-position of the phenyl group.2830-. (canceled)34. The method of claim 31 , wherein each Ris H.35. The method of claim 31 , wherein Ris H or methyl.36. The method of claim 31 , wherein Ris methyl.37. The method of claim 31 , wherein q is 0.38. The method of claim 31 , wherein v is 1 and X is in the 5-position of the thiopheno group.41. The method of claim 31 , wherein the neurodegenerative disease is Alzheimer's disease claim 31 , Parkinson's disease claim 31 , ALS claim 31 , or MS.42. The method of claim 31 , wherein the neurodegenerative disease is Alzheimer's disease. This application claims priority to U.S. Provisional Patent Application Ser. No. 61/139,751, filed Dec. 22, 2008, the entire content of which is incorporated herein by reference.The invention relates to methods of treatment or prevention of cancer and neurodegenerative diseases comprising administering an effective amount of a Sulfonamide-Based Compound to a subject.Alzheimer's disease (AD) is the most prevalent form of dementia. It is a neurodegenerative disorder, clinically characterized by progressive loss of memory and general cognitive function, and pathologically characterized by the deposition of extracellular proteinaceous plaques in the cortical and associative brain regions of sufferers. These plaques mainly comprise fibrillar aggregates of beta-amyloid peptide (Aβ). Aβ is formed from amyloid precursor protein (APP). APP is a ubiquitous membrane-spanning (type 1) glycoprotein, of which three major isoforms (APP695, APP751, and APP770) are known, that ...

Подробнее
20-06-2013 дата публикации

Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis

Номер: US20130158022A1
Принадлежит: CHINESE PLA GENERAL HOSPITAL

The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. 4. The compound according to having any one of the following structures claim 1 , or their isomers claim 1 , pharmaceutically acceptable salts and solvates:(1) (2E)-3-(2-thienyl)-N-[1-(8-quinolylamino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(2) (2E)-3-(3-thienyl)-N-[1-(8-quinolylamino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(3) (2E)-3-(2-thienyl)-N-[1-(4-tolylamino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(4) (2E)-3-(2-thienyl)-N-[1-(2-methoxyanilino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(5) (2E)-3-(2-thienyl)-N-(1-benzylaminothioformylamino-2,2,2-trichloroethyl)-2-acrylamide;(6) (2E)-3-(2-thienyl)-N-(1-cyclohexylaminothioformylamino-2,2,2-trichloroethyl)-2-acrylamide;(7) (2E)-3-(2-thienyl)-N-[1-isopropylaminothioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(8) (2E)-3-(2-thienyl)-N-[1-(2-fluoroanilino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(9) (2E)-3-(2-thienyl)-N-[1-(3-isopropoxypropylamino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(10) (2E)-3-(2-thienyl)-N-[1-(2-methoxyformylanilino)thioformylamino-2,2,2-trichloroethyl]-2-acrylamide;(11) (2E)-3-(2-thienyl)-N-(1-cycloheptylaminothioformylamino-2,2,2-trichloroethyl)-2-acrylamide;(12) (2E)-3-(2-thienyl)-N-[1-(1-morpholinyl)thioformylamino-2,2,2- ...

Подробнее
20-06-2013 дата публикации

METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO

Номер: US20130158082A1
Автор: Ye Keqiang
Принадлежит: EMORY UNIVERSITY

The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I. 2. The compound of claim 1 , wherein Rand Rare hydroxy substituted with formyl claim 1 , wherein formyl is substituted with R.3. The compound of claim 1 , wherein Ris a halogen.4. The compound of claim 1 , wherein Ris halogen.5. The compound of selected from:5,8-diacetyloxy-2,3-dichloro-1,4-naphthoquinone;5-acetyloxy-2,3-dichloro-1,4-naphthoquinone;2-((4-chlorophenyl)amino)naphtho[2,3-d]thiazole-4,9-dione, and2-((2,4-dichlorophenyl)amino)naphtho[2,3-d]thiazole-4,9-dione.6. A method of treating or preventing diabetes claim 1 , insulin resistance claim 1 , or hyperglycemia comprising administering to a subject diagnosed with claim 1 , at risk of claim 1 , or exhibiting symptoms of diabetes claim 1 , insulin resistance claim 1 , or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I claim 1 , as provide in .7. The use of a compound as provided in in the production of a medicament for the treatment of diabetes claim 1 , insulin resistance claim 1 , or hyperglycemia.8. A pharmaceutical composition comprising a compound of formula I a provided in .10. The method of claim 9 , wherein X is NH.11. The method of claim 9 , wherein Ris carbocyclyl claim 9 , aryl claim 9 , or heterocyclyl optionally substituted R.12. The method of claim 9 , wherein Ris a halogen.13. The method of claim 9 , wherein Rand Rare not hydroxy or alkoxy.14. The method of claim 9 , wherein Rand Rare hydrogen.15. The method of claim 9 , wherein the subject is diagnosed with Type 1 or Type 2 diabetes. This application claims priority to U.S ...

Подробнее
20-06-2013 дата публикации

TG2 INHIBITORS AND USES THEREOF

Номер: US20130158087A1

Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype. 76. Use of the compound of , , or for the manufacture of a medicament for treating cancer.83. The method of , , or , wherein the compound treats cancer. This patent application claims priority to U.S. Patent Application Ser. No. 61/356,961 filed on Jun. 21, 2010 which is incorporated by reference herein in its entiretyThis invention is related to modulation of aberrant expression of TG2 and/or inhibition of GTP binding to TG2 to treat cancer, metastasis, drug resistance and other oncogenic properties.None.None.This disclosure includes a sequence listing submitted as a text file pursuant to 37 C.F.R., §1.52(e)(v) named sequence listing.txt, created on Jun. 16, 2010, with a size of 22,111 bytes, which is incorporated herein by reference. The attached sequence descriptions and Sequence Listing comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §§1.821-1.825.Epithelial-to-mesenchymal transition (“EMT”) is a complex dynamic process that occurs during embryonic development for reprogramming of epithelial cells. Downregulation of E-cadherin, which occurs during EMT, results in the loss of homotypic adhesion. Reactivation of EMT during adult life has been associated with various pathological conditions. For example, EMT promotes the detachment of cancer cells from the primary tumor and facilitates migration through the acquisition of stem cell like properties, including loss of cellular polarity and adhesion. Metastasis and resistance to systemic therapies pose major clinical challenges to the treatment of breast and other cancers. Identification of tumor- ...

Подробнее
27-06-2013 дата публикации

SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

Номер: US20130165460A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. 2. A compound according to claim 1 , wherein:{'sup': '5', 'Ris S.'}3. A compound according to claim 1 , wherein:{'sup': '5', 'Ris —S(O)—.'}4. A compound according to claim 1 , wherein:{'sup': '5', 'sub': '2', 'Ris —S(O)—.'}5. A compound according to claim 1 , wherein:{'sup': '2', 'Ris methyl, isopropyl, 2-hydroxyethyl, methylpropionate, 2-methylpyridine, 3-methylpyridine, ethylacetate, N,N-dimethylpropanamide, N-isopropylpropanamide, N-(propan-2-yl)propanamide, propanamide hydroxycyclopent-3-yl, ethyl, N,N-dimethylacetamide, N-methylacetamide, 2-aminoethyl, H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl or ethyl-acetamide.'}6. A compound according to claim 1 , wherein:{'sup': '17', 'sub': '1-6', 'Ris H, substituted or unsubstituted Calkyl or halogen;'}{'sup': '18', 'sub': '1-6', 'Ris H, substituted or unsubstituted Calkyl or halogen;'}{'sup': '7', 'sub': 1-6', '1-6', '3-8, 'Ris halogen, CN, —OCalkyl, substituted or unsubstituted Calkyl or substituted or unsubstituted Ccycloalkyl; and'}{'sup': '8', 'sub': '1-6', 'Ris H, substituted or unsubstituted Calkyl or halogen.'}7. A compound according to claim 1 , wherein:{'sup': '17', 'Ris H;'}{'sup': '18', 'Ris H;'}{'sup': '7', 'sub': '1-6', 'Ris halogen, CN or —OCalkyl; and'}{'sup': '8', 'Ris H.'}8. A compound according to claim 1 , wherein:{'sup': '2', 'Ris methyl, isopropyl, 2-hydroxyethyl, methylpropionate, 2-methylpyridine, 3-methylpyridine, ethylacetate, N,N-dimethylpropanamide, N-isopropylpropanamide, N-(propan-2-yl)propanamide, propanamide hydroxycyclopent-3-yl, ethyl, N,N-dimethylacetamide, N-methylacetamide, 2-aminoethyl, H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl or ethyl-acetamide;'}{'sup': '5', 'sub': '2', 'Ris —S—, —S(O)—, or —S(O)—;'}{'sup': '17', 'Ris H;'}{'sup': '18', 'Ris H;'}{'sup': '7', 'sub': '1-6', ' ...

Подробнее
27-06-2013 дата публикации

Antiviral Drugs for Treatment of Arenavirus Infection

Номер: US20130165493A1
Принадлежит: Siga Technologies, Inc,

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). 167-. (canceled)68. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a pharmaceutically effective amount of a compound or a pharmaceutically-acceptable salt thereof , selected from the group consisting of2-Phenyl-cyclopropanecarboxylic acid [1-(4-amino-phenyl)-eth-(E)-ylidene]-hydrazide;Cyclopropanecarboxylic acid (4-[1-[(2-phenyl-cyclopropanecarbonyl)-hydrazono]-ethyl]-phenyl)-amide;2-Phenyl-cyclopropanecarboxylic acid [1-(2,4-dimethoxy-phenyl)-eth-(E)-ylidene]-hydrazide;2-Phenyl-cyclopropanecarboxylic acid [1-p-tolyl-eth-(E)-ylidene]-hydrazide;2-Phenyl-cyclopropanecarboxylic acid [1-biphenyl-4-yl-eth-(E)-ylidene]-hydrazide;2-Phenyl-cyclopropanecarboxylic acid [1-(3,4-dimethoxy-phenyl)-eth-(E)-ylidene]-hydrazide;Furan-2-carboxylic acid (4-[1-[(2-phenyl-cyclopropanecarbonyl)-hydrazono]-ethyl]-phenyl)-amide;2,4-Dichloro-N-(4-[1-[(2-Phenyl-cyclopropanecarbonyl)-hydrazono]-ethyl]-phenyl)-benzamide;2-Phenyl-cyclopropanecarboxylic acid [1-(2-hydroxy-phenyl)-eth-(E)-ylidene]-hydrazide;Thiophene-2-carboxylic acid (4-[1-[(2-phenyl-cyclopropanecarbonyl)-hydrazono]-ethyl]-phenyl)-amide;2-Phenyl-cyclopropanecarboxylic acid [1-(4-dimethylamino-phenyl)-eth-(E)-ylidene]-hydrazide;2-Phenyl-cyclopropanecarboxylic acid [1-(4-methoxy- ...

Подробнее
27-06-2013 дата публикации

METHOD FOR PREPARING 3-KETO-BENZOFURANE DERIVATIVES

Номер: US20130165673A1
Принадлежит: SANOFI

The invention relates to a method for preparing 3-keto-benzofurane derivatives of the general formula: Formula (I), where R is an alkyl or aryl group, Ris hydrogen or an alkyl or aryl group, and Ris a substituted alkyl or phenyl group. Said preparation method involves coupling a derivative of Formula III, where X is chlorine, bromine, or iodine or a sulfonate grouping: Formula (III) with a sulfonamide derivative of the formula R—SO—NHin the presence of a basic agent and a catalytic system formed of a complex between a palladium compound and a ligand. 2. The method as claimed in claim 1 , wherein:{'sub': 1', '1', '8, 'R or Rrepresents a linear or branched C-Calkyl group or a phenyl group that is substituted or unsubstituted,'}{'sub': 2', '1', '8', '1', '8', '1', '8', '1', '8, 'Rrepresents a linear or branched C-Calkyl group or a phenyl group of formula II in which Y represents chlorine, bromine or iodine or a linear or branched C-Calkoxy group or a dialkylaminoalkoxy group in which each linear or branched alkyl group is a C-Cand the linear or branched alkoxy group is a C-C.'}3. The method as claimed in claim 2 , wherein:{'sub': 1', '1', '4, 'R or Rrepresents a linear or branched C-Calkyl group,'}{'sub': 2', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents a linear or branched C-Calkyl group or a phenyl group of formula II in which Y represents a C-Calkoxy group or a dialkylaminoalkoxy group in which each linear or branched alkyl group is a C-Cand the linear or branched alkoxy group is a C-C.'}4. The method as claimed in one of to claim 2 , wherein R represents methyl claim 2 , Rrepresents n-butyl and Rrepresents 4-[3-(di-n-butylamino)-propoxy]-phenyl.5. The method as claimed in claim 1 , the palladium compound is bis(dibenzylideneacetone)palladium(0).6. The method as claimed in claim 1 , wherein the palladium compound is tris(dibenzylideneacetone)-dipalladium(0).7. The method as claimed in claim 1 , wherein the ligand is 2-(di-tert-butylphosphino)-2′ claim 1 ,4′ ...

Подробнее
11-07-2013 дата публикации

CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME

Номер: US20130175509A1
Принадлежит:

Embodiments of the present invention are directed to a condensed-cyclic compound and an OLED including the same. 5. The condensed-cyclic compound of claim 1 , wherein Xin Formula 2 is N(R) claim 1 , B(R) claim 1 , or Si(R)(R) claim 1 , wherein Rand Rare each independently hydrogen claim 1 , deuterium claim 1 , a halogen atom claim 1 , a hydroxyl group claim 1 , a cyano group claim 1 , a nitro group claim 1 , an amino group claim 1 , an amidino group claim 1 , hydrazine claim 1 , hydrazone claim 1 , a carboxylic acid group or a salt thereof claim 1 , a sulfonic acid group or a salt thereof claim 1 , a phosphoric acid group or a salt thereof claim 1 , a substituted or unsubstituted C-Calkyl group claim 1 , a substituted or unsubstituted C-Calkenyl group claim 1 , a substituted or unsubstituted C-Calkynyl group claim 1 , a substituted or unsubstituted phenyl group claim 1 , a substituted or unsubstituted pentalenyl claim 1 , a substituted or unsubstituted indenyl claim 1 , a substituted or unsubstituted naphthyl group claim 1 , a substituted or unsubstituted azulenyl claim 1 , a substituted or unsubstituted heptalenyl claim 1 , a substituted or unsubstituted indacenyl claim 1 , a substituted or unsubstituted acenaphthyl group claim 1 , a substituted or unsubstituted fluorenyl group claim 1 , a substituted or unsubstituted phenalenyl group claim 1 , a substituted or unsubstituted phenanthrenyl group claim 1 , a substituted or unsubstituted anthryl group claim 1 , a substituted or unsubstituted fluoranthenyl group claim 1 , a substituted or unsubstituted triphenylenyl group claim 1 , a substituted or unsubstituted pyrenyl group claim 1 , a substituted or unsubstituted chrysenyl group claim 1 , a substituted or unsubstituted naphthacenyl group claim 1 , a substituted or unsubstituted picenyl group claim 1 , a substituted or unsubstituted perylenyl group claim 1 , a substituted or unsubstituted pentaphenyl group claim 1 , a substituted or unsubstituted hexacenyl group ...

Подробнее
18-07-2013 дата публикации

COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME

Номер: US20130183252A1
Принадлежит: Senomyx, Inc.

The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals. 2. The compound of claim 1 , wherein X is selected from the group consisting of hydrogen claim 1 , heteroalkyl claim 1 , substituted heteroalkyl claim 1 , heteroaryl claim 1 , substituted heteroaryl claim 1 , heteroarylalkyl claim 1 , substituted heteroarylalkyl claim 1 , CN claim 1 , S(O)R claim 1 , CONRR claim 1 , —COR claim 1 , SONRR claim 1 , NRSOR claim 1 , NRSONRR claim 1 , B(OR)(OR) claim 1 , P(O)(OR)(OR) claim 1 , and P(O)(R)(OR).7. A composition comprising one or more compounds of claim 1 , or a salt claim 1 , hydrate claim 1 , solvate or N oxide thereof claim 1 , and one or more pharmaceutically acceptable carriers.8. The composition of claim 7 , which is a food claim 7 , beverage or medicament for human consumption.9. A coffee or coffee flavored food or beverage or medicament composition that comprises at least one compound of or a salt claim 1 , hydrate claim 1 , solvate or N oxide thereof.10. The composition of claim 9 , which is an instant coffee claim 9 , ground coffee claim 9 , or brewed coffee.11. The composition of claim 9 , which is an instant coffee.12. A food claim 1 , beverage claim 1 , or medicament composition having a bitter taste wherein said bitter taste is alleviated or eliminated by the addition of an effective amount of a compound of or a salt claim 1 , hydrate claim 1 , ...

Подробнее
18-07-2013 дата публикации

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Номер: US20130184222A1
Принадлежит: AGIOS PHARMACEUTICALS, INC

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here. 2. The compound of claim 1 , wherein Ris 3-fluorophenyl.3. The compound of or claim 1 , wherein:{'sup': '1', 'Ris selected from cyclohexyl, cyclopentyl, cycloheptyl, 3,3-difluorocyclobutyl, 4,4,-difluorocyclohexyl, and bicyclo[2.2.1]heptanyl; and'}{'sup': '4', 'Ris selected from 1-(methylmethoxycarbonylamino)ethyl, 1,2,3,4-tetrahydroquinolin-1-yl, 1-ethoxycarbonylpiperidin-2-yl, 1-ethoxycarbonylpyrrolidin-2-yl, 1H-benzimidazol-1-ylmethyl, 1H-indazol-3-ylmethyl, indolin-1-ylmethyl, 1H-indol-3-ylmethyl, 1H-indol-5-ylmethyl, 1H-pyrrolo[2,3-b]pyridine-3-ylmethyl, 1H-pyrrolo[3,2-b]pyridin-3-ylmethyl, 1-methoxycarbonylpiperidin-2-yl, 1-methoxycarbonylpyrrolidin-2-yl, 2-fluoropyridin-3-ylaminomethyl, 2-imino-4-fluoropyridin-1-ylmethyl, 2-methoxyphenylaminomethyl, 2-methyl-1H-benzimidazol-1-ylmethyl, 2-methylimidazol-1-ylmethyl, 2-trifluoromethyl-1H-imidazol-1-yl, 3-cyanophenylaminomethyl, 3-fluoropyridin-2-ylaminomethyl, 3-methoxyphenylaminomethyl, 4-(1,3,4-oxadiazole-2-yl)phenylaminomethyl, 4-(dimethylaminocarbonyloxy)phenylmethyl, 4,5-dichloroimidazol-1-ylmethyl, 4-cyanophenylaminomethyl, 4-fluorophenylaminomethyl, 4-fluoropyridin-2-ylaminomethyl, 4-hydroxyphenylmethyl, 4-methoxycarbonylmorpholin-3-yl, 4-methoxycarbonylpiperazin-1-ylmethyl, 4-methoxyphenylaminomethyl, 4-methylcarbonyloxyphenylmethyl, 5-fluoropyridin-2-aminomethyl, 5-fluoropyridin-2-oxymethyl, 6-fluoropyridin-3-ylaminomethyl, benzomorpholin-4-ylmethyl, methoxycarbonylaminomethyl, methylmethoxycarbonylaminomethyl, methylphenylaminomethyl, phenylaminomethyl, pyridin-2-oxymethyl, pyridin-2-ylaminomethyl, pyridin-2-yloxymethyl, pyridin-3-oxymethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, thiazol-4-ylmethyl, and thien-2-ylmethyl.'}4. The compound of claim 1 , wherein the compound is selected from any one of Compound numbers 104 claim ...

Подробнее
25-07-2013 дата публикации

BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS

Номер: US20130190356A1
Принадлежит: Genentech, Inc.

Compounds of the formula I: 2. The compound of claim 1 , wherein C is a group of formula (i).3. The compound of claim 2 , wherein A is a group of formula (a).4. The compound of claim 3 , wherein B is a group of formula (e).5. The compound of claim 3 , wherein B is a group of formula (f).6. The compound of claim 3 , wherein m is 0.7. The compound of claim 3 , wherein m is 1.8. The compound of claim 3 , wherein Rand Rare hydrogen.9. The compound of claim 3 , wherein Rand Rare hydrogen.10. The compound of claim 3 , wherein Ris: Calkyl; Ccycloalkyl; or Ccycloalkyl-Calkyl; each of which may be optionally substituted one or more times with halo.11. The compound of claim 3 , wherein Ris Calkyl.12. The compound of claim 3 , wherein Ris isobutyl.14. The compound of claim 13 , wherein Ris: —SO—R; —(CH)—C(O)—NRR; —(CH)—SO—NRR; —(CH)—NR—C(O)—R; or —(CH)—NR—SO—R.18. A composition comprising:(a) a pharmaceutically acceptable carrier; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(b) a compound of .'}19. A method for treating arthritis claim 1 , said method comprising administering to a subject in need thereof an effective amount of a compound of . This application claims the benefit under 35 USC §119 of U.S. Provisional Application Ser. No. 61/579,255 filed on Dec. 22, 2011, the disclosure of which is incorporated herein by reference.The invention pertains to compounds that modulate the function of retinoid-receptor related orphan receptor RORc (RORγ) and use of such compounds for treatment of autoimmune diseases.T helper 17 cells (Th17) are interleukin (IL)-17 secreting CD4+ T cells involved in pathogenesis of autoimmune diseases such as rheumatoid arthritis, irritable bowel disease, psoriasis, psoriatic arthritis and spondyloarthridities. The retinoic acid-related orphan receptor γ (RORγ or RORc) is recognized as a transcription factor necessary for Th17 cell differentiation. RORc is an orphan member of the nuclear hormone receptor subfamily that includes RORα (RORa) ...

Подробнее
25-07-2013 дата публикации

PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES

Номер: US20130190514A1
Принадлежит: TALLIKUT PHARMACEUTICALS, INC.

The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions for this use. 1. A composition comprising R- and S-enantiomers of N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea or pharmaceutically effective salts thereof wherein the composition comprises less than 2% of the S-enantiomer.2. The composition of claim 1 , wherein the composition comprises less than 1% of the S-enantiomer.3. The composition of claim 1 , wherein the composition consists of R- and S-enantiomers of N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea or pharmaceutically effective salts thereof.4. The composition of claim 3 , wherein the composition consists of less than 1% of the S-enantiomer.5. The composition of claim 1 , wherein the composition is provided in a unit dosage form for oral administration and wherein the composition is present in an amount of about 25-100 mg.6. The composition of claim 5 , wherein the composition is present in an amount of about 25 claim 5 , 50 claim 5 , 75 claim 5 , or 100 mg.7. The composition of claim 5 , wherein the composition is present in an amount of about 100 mg.8. The composition of claim 5 , wherein said unit oral dosage form is a tablet or capsule.9. The composition of for use in treating a leukotriene related pathology in a subject in need thereof.10. The composition for use of claim 9 , wherein the subject is a human.11. The composition for use of claim 9 , wherein the pathology is heart attack claim 9 , stroke claim 9 , peripheral arterial disease claim 9 , a cardiovascular disease claim 9 , an inflammatory disease claim 9 , a cancer claim 9 , ischemia induced myocardial injury claim 9 , central nervous system pathology resulting from formation of leukotrienes following stroke or subarachnoid hemorrhage claim 9 , allergy claim 9 , or a fibrotic disease.12. ...

Подробнее
25-07-2013 дата публикации

ESTERS OF 5-HYDROXYMETHYLFURFURAL AND METHODS FOR THEIR PREPARATION

Номер: US20130190516A1
Принадлежит: BATTELLE MEMORIAL INSTITUTE

Disclosed are compositions and methods for the production of mono-esters and di-esters from the reaction of HMF and a reactant selected from a diacid or a diacid derivative; typical reactants are PAN, phthaloyl dichloride, dimethyl phthalate, maleic acid, and maleic anhydride or mono-esters that can be prepared from HMF and MAN. 1. A method for making a di-ester comprising:mixing 5-(hydroxymethyl)-2-furfuraldehyde with an HCl scavenger and a solvent;cooling the mixture to between about −10° C. and about 10° C.;adding phthalolyl dichloride to the cooled mixture; andreacting the mixture while mixing for about 1 to about 3 hours.2. A method for di-ester synthesis from a mono-ester intermediate and 5-(hydroxymethyl)-2-furfuraldehyde , comprising:mixing a mono-ester of phthalic anhydride with a solvent;cooling the mixture to between about −10° C. to about 10° C.;adding a coupling agent and stirring for about 10 to 30 minutes;adding 5-(hydroxymethyl)-2-furfuraldehyde to the stirred mixture along with an optional catalyst; andreacting at the cooled temperature for about 2 to about 20 hours.3. The method according to wherein the coupling agent is a carbodiimide or an activated ester reagent.4. A method for di-ester synthesis comprising:mixing 5-(hydroxymethyl)-2-furfuraldehyde and dimethyl phthalate with a suitable catalyst; andheating at about 80° C. to about 110° C. while stirring for about 2 to about 4 hours.5. A method for di-ester synthesis comprising:melting 5-(hydroxymethyl)-2-furfuraldehyde:adding phthalic anhydride and an optional esterification catalyst to the molten 5-(hydroxymethyl)-2-furfuraldehyde while stirring; andreacting the mixture while stirring for about 16 to about 30 hours at a temperature between about 110° C. to about 140° C.6. A method for di-ester synthesis comprising;mixing a mono-ester reaction product of 5-(hydroxymethyl)-2-furfuraldehyde and phthalic anhydride with a molar equivalent of a coupling reagent;adding 5-(hydroxymethyl)-2- ...

Подробнее
08-08-2013 дата публикации

TRIPHENYLENE-BASED MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES

Номер: US20130200359A1
Принадлежит: Merck Patent GmBH

The present invention relates to compounds of the formula (1) and (2) which are suitable for use in electronic devices, in particular organic electroluminescent devices. 115-. (canceled)19. The compound according claim 16 , wherein claim 16 , in compounds of the formula (1) where n=0 or in compounds of the formula (4) or formula (4a) claim 16 , X is selected from the group consisting of C(R) claim 16 , Si(R)and N(R) and Rstands claim 16 , identically or differently on each occurrence claim 16 , for an aromatic or heteroaromatic ring system having 5 to 40 aromatic ring atoms claim 16 , which may in each case also be substituted by one or more radicals Rand where two radicals Rmay also form an aromatic ring system with one another;and in that, in compounds of the formula (1) where X=formula (3) or in compounds of the formula (5) or formula (5a), the two triphenylene moieties which are bonded to A are in each case substituted identically and A stands for carbon or silicon;{'sup': 2', '2', '2', '2', '2', '2', '2', '2, 'sub': 2', '2', '2', '2, 'and in that, in compounds of the formula (1) where n=1 or in compounds of the formula (6) or formula (6a), the group X—Y—X is selected from the group consisting of C(R)—O—C(R), Si(R)—O—Si(R), O—BR—O, O—PR—O, O—P(═O)R—O and C(═O)—NR—C(═O);'}and in that, in compounds of the formula (2) or (7) or (7a), the two radicals R are identical.20. A process for the preparation of the compound according to which comprises reacting 1 claim 16 ,12-dilithiotriphenylene derivatives with electrophiles or by reaction of halogen- or amino-substituted triphenylene derivatives in a metal-catalyzed coupling reaction.21. An oligomer claim 16 , polymer or dendrimer containing one or more of the compounds according to claim 16 , where one or more bonds are present from the compound to the polymer claim 16 , oligomer or dendrimer.22. An electronic device which comprises the compound according to .23. An electronic device which comprises the oligomer claim ...

Подробнее
08-08-2013 дата публикации

COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Номер: US20130203706A1
Автор: Green Jeremy
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

A compound is represented by Structural Formula (I): 2. The compound of claim 1 , wherein:{'sup': a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'E', 'E', 'F', 'F, 'sub': 2', '2', '2', '2', '3-8', '6-10, 'each Q independently is selected from the group consisting of halogen, cyano, nitro, —OR, —SR, —S(O)R, —SOR, —NRR, —C(O)R, —C(O)OR, —OC(O)R, —NRC(O)R, —C(O)NRR, —NRC(O)NRR, —NRC(O)OR, —NRC(═NR)NRR, —OCONRR, —C(O)NRC(O)OR, —C(═NR)R, —C(═NOR)R, —SONRR, —NRSOR, —NRSONRR, —OP(O)(OR)OR, Ccarbocycle optionally substituted with one or more instances of J, 4-8 membered heterocycle optionally substituted with one or more instances of J, Caryl group optionally substituted with one or more instances of J, and 5-10 membered heteroaryl group optionally substituted with one or more instances of J;'}{'sub': 3-6', '4-6', '2', '2, 'sup': '1', 'Y is optionally substituted Ccycloalkyl, optionally substituted Ccycloalkenyl, —(Caliphatic group)-R, optionally substituted phenyl, or optionally substituted 5-6 membered heteroaryl, and wherein said Caliphatic group is optionally substituted; and'}{'sup': Y', 'a', 'a', 'a', 'a, 'each Jis independently selected from the group consisting of halogen, —CN, nitro, R, —OR, —COR, and —NRR.'}312-. (canceled)13. The compound of claim 2 , wherein Y is —(Caliphatic group)-Ror phenyl optionally substituted with one or more instances of Jindependently selected from the group consisting of chloro claim 2 , fluoro claim 2 , —CN claim 2 , nitro claim 2 , methyl claim 2 , ethyl claim 2 , —CF claim 2 , —OH claim 2 , —OMe claim 2 , —NH claim 2 , and —C(O)Me claim 2 , and wherein said Caliphatic group is optionally substituted.14. (canceled)15. The compound of claim 13 , wherein Y is —CH—CH—R claim 13 , —CH═CH—R claim 13 , or —C≡CR.1722-. (canceled)23. The compound of claim 16 , wherein:{'sup': '3', 'sub': '1-6', 'each Rindependently is —H or optionally substituted Calkyl;'}{'sup': 4', '6, 'sub': '1 ...

Подробнее
08-08-2013 дата публикации

PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF

Номер: US20130204013A1
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. 110-. (canceled)12. The dihydrothiophene compound according to claim 11 , wherein:{'sup': '1', 'sub': 6-10', '1-10', '1-10', '1-10', '1-10, 'Ris a Caryl group unsubstituted or substituted with one or more halogen atoms, one or more Calkyl groups or one or more Calkoxy groups, such that the Calkyl groups and the Calkoxy groups are unsubstituted or substituted with one or more halogen atoms;'}{'sup': '2', 'sub': '1-3', 'Ris a Calkyl group unsubstituted or substituted with one or more halogen atoms; and'}{'sup': '3', 'Ris a hydrogen atom or a methyl group.'}13. The dihydrothiophene compound according to claim 12 , wherein Ris a phenyl group unsubstituted or substituted with one or more halogen atoms claim 12 , one or more Calkyl groups or one or more Calkoxy groups claim 12 , such that the Calkyl groups and the Calkoxy groups are unsubstituted or substituted with one or more halogen atom. The present invention relates to a process for producing, from a 2-aryl acetate compound, a corresponding 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof.2-Aryl-3-hydroxy-4-substituted carbonyl thiophene compounds are compounds useful, for example, as intermediates for synthesis of thrombopoietin receptor activators (e.g. Patent Document 1).As a process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound, only a process of synthesizing a 2-aryl-3-hydroxy-4-ester thiophene compound by a known production process (e.g. Patent Document 2), and converting the ester group at the 4-position to an alkylcarbonyl group has been known (e.g. Patent Document 1). However, conversion of the ester group to an alkylcarbonyl group requires multiple steps, and thus a production process with a smaller number of steps has been desired.As ...

Подробнее
08-08-2013 дата публикации

Method for preparing 2-hydroxybutyrolactone

Номер: US20130204016A1
Принадлежит: Adisseo France SAS

The invention relates to a method for preparing 2-hydroxybutyrolactone (2HBL) from a compound or its salt or its oligomers, said compound fitting formula (I) CH 3 —S—CH 2 CH 2 CR1R2R3 Wherein R1 represents H R2 represents a group selected from OH; OR4 and OCOR4 wherein R4 represents a group selected from linear, cyclic, alicyclic or branches alkyl groups having from 1 to 10 carbon atoms, and aryl groups having from 6 to 10 carbon atoms, optionally substituted with substituent(s) selected from linear or branched alkyl groups having from 1 to 10 carbon atoms, halogens and hydroxyl, amino, nitro and alkoxy groups having from 1 to 10 carbon atoms; and OSiRR′R″ wherein R, R′ and R″ are selected independently of each other from linear, cyclic, alicyclic or branched alkyl groups having from 1 to 10 carbon atoms, aryl groups having from 6 to 10 carbon atoms, optionally substituted with substituent(s) selected from linear or branched alkyl groups having from 1 to 10 carbon atoms, or R1 and R2 represent together ═O, R3 represents COOH or a COOR5 group wherein R5 represents a group selected from linear, cyclic, alicyclic or branched alkyl groups having from 1 to 10 carbon atoms, benzyl groups and benzyl groups substituted with one or two substituents selected from linear or branched alkyl groups having from 1 to 10 carbon atoms, halogens and hydroxyl, amino, nitro and alkoxy groups having from 1 to 10 carbon atoms, or R3 represents a cyano group, method according to which a sulfonium of said compound is obtained, said sulfonium fitting the formula (II) [CH 3 ][CH 2 CH 2 CR1R2CR3][CR6R7R8]S + X − wherein R1, R2 and R3 have the above definition, and R6 and R7 are selected independently of each other from H, linear, cyclic, alicyclic or branched alkyl groups having from 1 to 10 carbon atoms, and aryl groups having from 6 to 10 carbon atoms, optionally substituted with substituent(s) selected from linear or branched alkyl groups having from 1 to 10 carbon atoms, halides and ...

Подробнее
15-08-2013 дата публикации

STRUCTURE, SYNTHESIS, AND APPLICATIONS FOR POLY (PHENYLENE) ETHYNYLENES (PPEs)

Номер: US20130210828A1
Принадлежит:

The present disclosure provides novel poly(phenylene ethynylene) (PPE) compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various PPEs show antibacterial, antiviral and antifungal activity. 2. The poly-(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X claim 1 , Y claim 1 , and Z=H and Z=O(CH)(CHN)CH.3. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X claim 1 , Y claim 1 , and Z=H and Z=O(CH)SO.4. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X and Y=H claim 1 , Z=O(CH)N(CH) claim 1 , and Z=(OCHCH)OCH.5. The poly(phenylene ethynylene) of wherein k=6.6. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X and Y=H claim 1 , Z=O(CH)N(CH) and Z=(OCHCH)OCH.7. The poly(phenylene ethynylene) of wherein A=CCHS claim 1 , B=CCH claim 1 , C is not present claim 1 , X and Y=H claim 1 , Z=O(CH)N(CH) and Z=H.8. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C=CH claim 1 , X=[CCH]COOCHCH claim 1 , Y=COOCHCH claim 1 , Z=O(CH)N(CH) and Z=H.9. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C=CH claim 1 , X=[CCH]COOCHCH claim 1 , Y=COOCHCH claim 1 , Z=O(CH)(CHN)CH and Z=H.10. The poly(phenylene ethynylene) of wherein A=CCHS claim 1 , B=CCH claim 1 , C=CH claim 1 , X=[CCH]COOCHCH claim 1 , Y=COOCHCH claim 1 , Z=O(CH)N(CH) and Z=H.11. The poly(phenylene ethynylene) of wherein k=3.12. The poly(phenylene ethynylene) of wherein the poly(phenylene ethynylene) exhibits biocidal activity.13. The poly(phenylene ethynylene) of wherein the poly(phenylene ethynylene) exhibits antiviral activity.14. The poly(phenylene ethynylene) of wherein the poly(phenylene ethynylene) exhibits antifungal activity.15. The poly(phenylene ethynylene) of functionally attached to a material or substance so that the poly(phenylene ethynylene) can interfere ...

Подробнее
15-08-2013 дата публикации

SYNTHESIS OF BICYCLIC COMPOUNDS AND METHOD FOR THEIR USE AS THERAPEUTIC AGENTS

Номер: US20130210904A1
Принадлежит:

Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addition/cyclization sequence followed by functional group manipulation to develop functionalized compounds that can target neuraminidase, which makes them ideal candidates for treating influenza. Pharmaceutical compositions comprising the therapeutic compounds and biologically-acceptable materials are also described. Methods of inhibiting neuraminidase in subjects that are suspected of containing neuraminidase are also described. The use of metabolites of the disclosed compounds can also be used in diagnostic assays for therapeutic dosing of the disclosed compounds. 2. The compound according to where the heteroatom-containing moiety is selected from aldehyde claim 1 , acyl halide claim 1 , carbonate claim 1 , carboxyl claim 1 , carboxylate claim 1 , ether claim 1 , ester claim 1 , hydroxyl claim 1 , ketone claim 1 , silyl ether claim 1 , peroxy claim 1 , hydroperoxy claim 1 , phosphate claim 1 , phosphonate claim 1 , phosphoryl claim 1 , phosphodiester claim 1 , phosphine claim 1 , pyrrole claim 1 , thiol claim 1 , thioether/sulfide claim 1 , disulfide claim 1 , sulfonyl claim 1 , sulfonyl claim 1 , carbonothioyl claim 1 , sulfino claim 1 , sulfo claim 1 , thiocyanate claim 1 , isothiocyanate claim 1 , oxazole claim 1 , oxadiazole claim 1 , imidazole claim 1 , triazole claim 1 , tetrazole claim 1 , amine claim 1 , amide claim 1 , azide claim 1 , azo claim 1 , cyano claim 1 , isocyanate claim 1 , imide claim 1 , nitrile claim 1 , isonitrile claim 1 , nitro claim 1 , nitroso claim 1 , nitromethyl claim 1 , selenol claim 1 , guanidino claim 1 , and substituted guanidino.4. The compound according to where Vis CRR claim 3 , C(R) claim 3 , or C(R) claim 3 , and any one of R claim 3 , R claim 3 , or Rtogether with Rform a lactam or lactone.5. ...

Подробнее
22-08-2013 дата публикации

PHENOXY DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS

Номер: US20130217651A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel phenoxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. 2. A compound according to wherein Lis CH.3. A compound according to wherein Lis CH.4. A compound according to wherein a is 1 claim 1 , 2 or 3.8. A compound according to selected from:3-[(4-{[5-(3-chlorophenyl)-6-(3,4-dimethylphenyl)hexyl]oxy}benzyl)amino]propanoic acid;3-({4-[3-(3-chlorophenyl)-4-(3,4-dimethylphenyl)butoxy]benzyl}amino)propanoic acid;{3-[(4-{[5-(3-chlorophenyl)-6-(3,4-dimethylphenyl)hexyl]oxy}benzyl)amino]propyl}phosphonic acid;[3-({4-[3-(3-chlorophenyl)-4-(3,4-dimethylphenyl)butoxy]benzyl}amino) propyl]phosphonic acid;3-[(4-{[4-(3,5-difluorophenyl)-5-(3,4-dimethylphenyl)pentyl]oxy}benzyl)amino]propanoic acid;3-[(4-{[4-(3-chlorophenyl)-5-(3,4-dimethylphenyl)pentyl]oxy}benzyl)amino]propanoic acid;{3-[(4-{[4-(3,5-difluorophenyl)-5-(3,4-dimethylphenyl)pentyl]oxy}benzyl)amino]propyl}phosphonic acid;{3-[(4-{[4-(3-chlorophenyl)-5-(3,4-dimethylphenyl)pentyl]oxy}benzyl)amino]propyl}phosphonic acid;3-[(4-{[5-(3,4-dimethylphenyl)-4-(3-thienyl)pentyl]oxy}benzyl)amino]propanoic acid;3-[(4-{[5-(3,4-dimethylphenyl)-4-(3-thienyl)pentyl]oxy}benzyl)amino]propyl}phosphonic acid; and3-[(4-{[4-(2,3-difluorophenyl)-5-(3,4-dimethylphenyl)pentyl]oxy}benzyl)amino]propanoic acid.9. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to and a pharmaceutically acceptable adjuvant claim 1 , diluents or carrier.10. A pharmaceutical composition according to wherein the compound is selected from:3-[(4-{[5-(3-chlorophenyl)-6-(3,4-dimethylphenyl)hexyl]oxy}benzyl)amino]propanoic acid;3-({4-[3-(3-chlorophenyl)-4-(3,4-dimethylphenyl)butoxy]benzyl}amino)propanoic acid;{3-[(4-{[5-(3-chlorophenyl)-6-(3,4-dimethylphenyl)hexyl]oxy}benzyl)amino]propyl}phosphonic acid;[3-({4-[3-(3-chlorophenyl)-4-(3,4- ...

Подробнее
22-08-2013 дата публикации

Sulphonamine Compounds and Methods of Making and Using Same

Номер: US20130217759A1
Принадлежит: Zafgen Inc.

The invention provides sulphonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. 2. The compound of claim 1 , wherein A is phenyl.3. The compound of claim 1 , wherein A is pyridinyl.4. The compound of claim 1 , wherein X is S or NR.5. The compound of claim 1 , wherein X is S.6. The compound of wherein Ris H.7. The compound of claim 1 , wherein Ris selected from the group consisting of H claim 1 , Calkoxy claim 1 , Calkyl claim 1 , Calkenyl claim 1 , Calkynyl claim 1 , Ccycloalkyl claim 1 , Calkoxy claim 1 , CcycloalkylCalkyl- claim 1 , Calkyl-S(O)— wherein w is 0 claim 1 , 1 or 2 claim 1 , Calkyl-N(R)-carbonyl claim 1 , Calkyl-carbonyl-N(R)— claim 1 , Calkyl-N(R)-carbonyl-N(R)— claim 1 , and Calkyl-N(R)— claim 1 , wherein Calkyl claim 1 , Calkoxy claim 1 , Calkenyl claim 1 , Ccycloalkyl and Calkynyl may be optionally substituted by RRN—.8. The compound of claim 1 , wherein Ris selected from the group consisting of Calkyl claim 1 , phenyl or heteroaryl.9. The compound of claim 1 , wherein Ris selected from the group consisting of H claim 1 , Calkyl claim 1 , or Calkoxy claim 1 , wherein Calkyl or Calkoxy is optionally substituted by one or more substituents selected from halogen and RRN—.11. The compounds 2-benzenesulphonylamino-4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid claim 1 , 2-(4-fluorobenzenesulphonylamino)-4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid claim 1 , 2-benzenesulphonylaminobenzo[b]thiophene-3-carboxylic acid claim 1 , 2-benzenesulphonylamino-5-ethyl-4-methylthiophene-3-carboxylic acid claim 1 , 2-benzenesulphonylamino-4 claim 1 ,7-dihydro-5H-thieno[2 claim 1 ,3-c]pyran-3-carboxylic acid claim 1 , 2-benzenesulphonylamino-5-phenylthiophene-3-carboxylic acid claim 1 , 2- ...

Подробнее
22-08-2013 дата публикации

NOVEL PHASE TRANSFER CATALYSTS

Номер: US20130217889A1
Принадлежит: NATIONAL UNIVERSITY OF SINGAPORE

Compounds of formula (I): wherein Rto R, and X are defined herein. Also disclosed are methods of making and using these compounds. 2. The compound of claim 1 , wherein Ris identical to R claim 1 , Ris identical to R claim 1 , Ris identical to R claim 1 , and Ris identical to R.3. The compound of claim 2 , wherein all the carbon atoms to which R claim 2 , R claim 2 , R claim 2 , and Rare attached have an R or S configuration.4. The compound of claim 3 , wherein all the carbon atoms to which R claim 3 , R claim 3 , R claim 3 , and Rare attached have an R configuration claim 3 , or all of them have a S configuration.5. The compound of claim 4 , wherein each of R claim 4 , R claim 4 , R claim 4 , and R claim 4 , independently claim 4 , is aryl or heteroaryl.6. The compound of claim 4 , wherein Rand R claim 4 , together with the two carbon atoms to which they are attached claim 4 , form C-Ccycloalkyl; and Rand R claim 4 , together with the two carbon atoms to which they are attached claim 4 , form C-Ccycloalkyl.7. The compound of claim 4 , wherein each of R claim 4 , R claim 4 , R claim 4 , and R claim 4 , independently claim 4 , is C-Calkyl.9. The compound of claim 1 , wherein Ris identical to R claim 1 , each of Rand Ris H claim 1 , and Ris identical to R.10. The compound of claim 9 , wherein all the carbon atoms to which Rand Rare attached have an R or S configuration.11. The compound of claim 10 , wherein each of Rand R claim 10 , independently claim 10 , is aryl or heteroaryl.12. The compound of claim 10 , wherein each of R claim 10 , R claim 10 , R claim 10 , and R claim 10 , independently claim 10 , is C-Calkyl.13. The compound of claim 1 , wherein Ris identical to R claim 1 , each of Rand Ris H claim 1 , and Ris identical to R.14. The compound of claim 13 , wherein all the carbon atoms to which Rand Rare attached have an R or S configuration.15. The compound of claim 14 , wherein each of Rand R claim 14 , independently claim 14 , is aryl or heteroaryl.16. The ...

Подробнее
22-08-2013 дата публикации

ORGANIC AMINE SALTS OF AMINOBENZOIC ACID DERIVATIVES AND METHOD FOR PRODUCING SAME

Номер: US20130217894A1
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

A novel organic amine salt or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid having useful properties as a drug is provided. 1. An organic amine salt of , or a salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid.2. The salt according to claim 1 , wherein the organic amine claim 1 , or the quaternary ammonium salt claim 1 , comprises a hydroxy group.3. The salt according to claim 2 , wherein the organic amine claim 2 , or the quaternary ammonium salt claim 2 , comprising the hydroxy group is ethanolamine claim 2 , tromethamine or choline.4. An ethanolamine salt of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid.5. A tromethamine salt of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid.6. A choline salt of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid.7. A medicine claim 1 , comprising the salt of as an active ingredient.8. The medicine according to claim 7 , which is a thrombopoietin receptor activator.9. The medicine according to claim 7 , which is a platelet increasing agent.10. A method for producing the salt of claim 1 , comprising reacting 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid with the organic amine claim 1 , or the quaternary ammonium salt claim 1 , in a solvent.11. The method according to claim 10 , wherein the reacting occurs at 0 to 70° C. claim 10 , and a resulting organic amine salt claim 10 , or salt with quaternary ammonium ion claim 10 , is crystallized.12. The method according to claim 10 , wherein the organic amine claim 10 , or the quaternary ammonium salt claim 10 , is ethanolamine claim 10 , ...

Подробнее
29-08-2013 дата публикации

SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT

Номер: US20130225619A1
Принадлежит: Acucela Inc.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted heterocyclic amine derivative compound and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. 14. The compound of wherein Y is alkyl claim 1 , carbocyclyl or heterocyclyl.15. The compound of wherein Y is —C(R)(R)(R);{'sup': 16', '17', '16', '17, 'sub': 1', '13, 'Rand Rare each independently selected from hydrogen, C-Calkyl, halo or fluoroalkyl; or Rand R, together with the carbon to which they are attached form a carbocyclyl or heterocyclyl; and'}{'sup': '18', 'Ris selected from a hydrogen, alkyl, alkoxy, hydroxy, halo or fluoroalkyl.'}16. The compound of wherein Rand R claim 15 , together with the carbon to which they are attached claim 15 , form a carbocyclyl or heterocyclyl.17. The compound of wherein Rand R claim 16 , together with the carbon to which they are attached claim 16 , form a cyclobutyl claim 16 , cyclopentyl claim 16 , cyclohexyl claim 16 , cycloheptyl claim 16 , or cyclooctyl claim 16 , and Ris hydrogen or hydroxy.18. The compound of wherein Rand R claim 17 , together with the carbon to which they are attached claim 17 , form a cyclopentyl claim 17 , cyclohexyl claim 17 , or cycloheptyl claim 17 , and Ris hydrogen or hydroxy.19. The compound of wherein Rand Ris independently selected from C-Calkyl; and Ris hydrogen claim 15 , hydroxy or alkoxy.20. The compound of wherein X is selected from —O—C(R) claim 1 , —S(O)—C(R)— claim 1 , —SO(NR)— claim 1 , —NR—C(R)— claim 1 , —NR—C(═O)— claim 1 , and —NR—S(O)—.21. The compound of wherein X is selected from —C(R)—C(R)— claim 1 , —C(R)═C(R)— claim 1 , —C≡C— claim 1 , —C(═O)—N(R)— claim 1 , —C(R)—O— claim 1 , and —C(R)—NR.22. The ...

Подробнее
29-08-2013 дата публикации

Regeneration of Selective Solvents for Extractive Processes

Номер: US20130225838A1
Принадлежит:

Recovering a polar hydrocarbon (HC) selective solvent substantially free of hydrocarbons (HCs) and other impurities from a lean solvent stream containing the selective solvent, measurable amounts of heavy aromatic HCs, and polymeric materials that are generated in an extractive distillation (ED) or liquid-liquid extraction (LLE) process. At least a portion of the lean solvent stream is contact in a solvent clean-up zone with a slip stream from the HC feed stream of the ED or LLE process or an external stream. The HC feed stream, such as pyrolysis gasoline or reformate, contains significant amounts of benzene and at least 50% polar (aromatic) HCs and serves as a displacement agent to remove the heavy HCs and polymeric material from the lean solvent stream. A magnetic filter can be used to remove the paramagnetic contaminants from the lean solvent. 1. A method of recovering a polar hydrocarbon selective solvent substantially free of hydrocarbons and other impurities from a solvent-rich stream containing selective solvent , measurable amounts of heavy hydrocarbons , and polymeric materials generated from reactions among thermally decomposed or oxidized solvent , heavy hydrocarbons , and additives , which method comprises the steps of:(a) providing a feed stream containing polar and less polar hydrocarbons;(b) introducing the feed stream into an extraction zone, which includes an extractive distillation column or a liquid-liquid extraction column, to yield (i) a less polar hydrocarbon stream with an associated first water stream and (ii) a polar hydrocarbon stream with associated lean solvent stream and second water stream; and(c) introducing a portion of the lean solvent stream into a solvent cleanup zone at a first location and introducing (i) a slip stream from the feed stream or (ii) an external stream comprising polar hydrocarbons and having a boiling point range that at least partially matches that of the feed stream into the solvent cleanup zone at a second ...

Подробнее
12-09-2013 дата публикации

AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS

Номер: US20130236434A1
Принадлежит: TEXAS HEART INSTITUTE

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. 2. A compound of selected from the group consisting of methyl(6S claim 1 ,10S)-10-(1 claim 1 ,3-benzodioxol-5-yl)-6-butyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl(6S claim 1 ,10R)-10-(1 claim 1 ,3-benzodioxol-5-yl)-6-butyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl(6S claim 1 ,10S)-10-(1 claim 1 ,3-benzodioxol-5-yl)-6-butyl-7-methyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl(6S claim 1 ,10S)-10-(1 claim 1 ,3-benzodioxol-5-yl)-6-butyl-9-methyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; ethyl(6S claim 1 ,10R)-10-(1 claim 1 ,3-benzodioxol-5-yl)-6-butyl-7-methyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl(10S)-10-(1 claim 1 ,3-benzodioxol-5-yl)-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl 3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl(6S claim 1 ,10S)-10-(1 claim 1 ,3-benzodioxol-5-yl)-6-butyl-2-methyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-4-oxa-2 claim 1 ,7 claim 1 ,9-triazadodecan-12-oate; methyl(6S)-6-butyl-3 claim 1 ,8-dioxo-1-(2-thienyl)-2-(2- ...

Подробнее
12-09-2013 дата публикации

SULFAMIDES AS TRPM8 MODULATORS

Номер: US20130237547A1
Автор: Matthews Jay M.
Принадлежит: Janssen Pharmaceutica, NV

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: 1. (canceled)312-. (canceled)17. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 2 , a pharmaceutically acceptable excipient claim 2 , and a pharmaceutically acceptable diluent.18. A pharmaceutical composition of claim 17 , wherein the composition is a solid claim 17 , oral dosage form.19. A pharmaceutical composition of claim 17 , wherein the composition is a syrup claim 17 , an elixir claim 17 , or a suspension.20. A method for treating neuropathic pain in a subject in need thereof claim 2 , comprising administering to the subject a therapeutically effective amount of a compound of .21. The method of wherein the neuropathic pain is due to cancer claim 20 , a neurological disorder claim 20 , spine or peripheral nerve surgery claim 20 , a brain tumor claim 20 , traumatic brain injury (TBI) claim 20 , spinal cord trauma claim 20 , a chronic pain syndrome claim 20 , fibromyalgia claim 20 , chronic fatigue syndrome claim 20 , a neuralgia claim 20 , lupus claim 20 , sarcoidosis claim 20 , peripheral neuropathy claim 20 , bilateral peripheral neuropathy claim 20 , diabetic neuropathy claim 20 , central pain claim 20 , neuropathies associated with spinal cord injury claim 20 , stroke claim 20 , ALS claim 20 , Parkinson's disease claim 20 , multiple sclerosis claim 20 , sciatic neuritis claim 20 , mandibular joint neuralgia claim 20 , peripheral neuritis claim 20 , polyneuritis claim 20 , stump pain claim 20 , phantom limb pain claim 20 , a bony fracture claim 20 , oral neuropathic pain claim 20 , Charcot's pain claim 20 , complex regional pain syndrome I and II (CRPS I/II) claim 20 , radiculopathy claim 20 , Guillain-barre syndrome claim 20 , meralgia paresthetica claim 20 , burning-mouth syndrome claim 20 , optic ...

Подробнее
19-09-2013 дата публикации

NOVEL NEUROTRYPSIN INHIBITORS

Номер: US20130245064A1
Принадлежит:

The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein Ris phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by optionally substituted phenyl, or bicyclic heteroaryl, Ris hydrogen or methyl, and Rand Rhave the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers. 2. The compound according to of formula (I) wherein{'sup': '1', 'sub': 5', '6, 'Ris optionally substituted biphenylyl, phenoxyphenyl or phenylaminophenyl, optionally substituted 1H-benzimidazol-2-yl-phenyl, optionally substituted benzo-C- or C-cycloalkyl or -cycloalkenyl, optionally substituted phenyl-thiophenyl or benzothiophenyl, optionally substituted 1H-benz[d]imidazol-2-yl, optionally substituted indolyl, optionally substituted quinolinyl, or optionally substituted phenyl-1,3-thiazol-2-yl or benzo-1,3-thiazol-2-yl;'}{'sup': '2', 'Ris hydrogen or methyl;'}{'sup': '3', 'Ris alkyl, optionally substituted benzyl, optionally substituted phenylethyl, optionally substituted phenyl; and'}{'sup': '4', 'Ris hydrogen or lower alkyl; or'}{'sup': 3', '4, 'Rand Rtogether with the nitrogen atom, to which they are bound, are optionally substituted pyrrolidino, optionally substituted piperidino, 1,2,3,4-tetrahydro-quinol-1-yl or 1,2,3,4-tetrahydro-isoquinol-2-yl, morpholino, or optionally substituted piperazino.'}3. The compound according to of formula (I) wherein{'sup': '1', 'Ris optionally substituted biphenylyl, phenoxyphenyl or phenylaminophenyl with one to three substituents, wherein the substituents are selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halo or cyano; 1H-benzimidazol-2-yl-phenyl optionally substituted at nitrogen by methyl or carboxymethyl and at the benzo residue by carboxy, chloro or dichloro; 2-indanyl ...

Подробнее
19-09-2013 дата публикации

NATURAL PRODUCT ANTIBIOTICS AND ANALOGS THEREOF

Номер: US20130245130A1
Принадлежит:

Provided herein are pure and isolated natural products and analogs thereof of Formula (I), (II), (III), and (IV), pharmaceutical compositions thereof, and methods of use, for example, for treating a bacterial infection. Further provided are methods useful in identifying an inhibitor of bacterial sugar fermentation in a bacterial strain, such as a compound (inhibitor) of Formula (I), (II), (III), or (IV): 5Escherichia coli, Pseudomonas aeruginosa, Vibrio cholerae, K. pneumoniaeStaphylococcus aureusMycobacterium tuberculosis. The method of claim 4 , wherein the bacterial infection is an claim 4 , methicillin-resistant claim 4 , or infection.715-. (canceled)1730-. (canceled)31. The pure and isolated compound of claim 1 , wherein Ris hydrogen.32. The pure and isolated compound of claim 1 , wherein Ris hydrogen.33. The pure and isolated compound of claim 1 , wherein Ris substituted or unsubstituted C-Calkyl.34. The pure and isolated compound of claim 1 , wherein at least one instance of Rand Ris hydrogen.35. The pure and isolated compound of claim 1 , wherein each instance of Rand Ris hydrogen.36. The pure and isolated compound of claim 1 , wherein Rand Rare the same group.37. The pure and isolated compound of claim 1 , wherein each of Rand Rare independently hydrogen or —C(═O)CH.38. The pure and isolated compound of claim 1 , wherein each of R claim 1 , R claim 1 , and Rare the same group.39. The pure and isolated compound of claim 1 , wherein each of R claim 1 , R claim 1 , and Rare independently hydrogen or —C(═O)CH. The present application claims the benefit under 35 U.S.C. §119(e) of U.S. provisional patent application, U.S. Ser. No. 61/602,304, filed Feb. 23, 2012, which is incorporated herein by reference.The emergence of bacteria with resistance to multiple antimicrobial agents has increased the need to discover new antibiotics.The emergence of bacteria with resistance to multiple anti-microbial agents has motivated the development of high throughput chemical ...

Подробнее
19-09-2013 дата публикации

HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS

Номер: US20130245255A1
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. 1. A compound represented by the formula (I):{'sup': 1', '2', '3', '4, 'sub': 1-10', '1-10, 'wherein each of R, R, Rand Ris independently a hydrogen atom or a Calkyl group (the Calkyl group may be optionally substituted with one or more halogen atoms),'}{'sup': 5', '1', '1', '1', '8', '9', '1', '8', '9', '10', '10', '11', '12', '11', '12', '13', '14', '13', '14', '11', '12', '11', '12', '15', '9', '2', '2', '16', '17', '16', '17', '3', '3', '2', '18', '19', '2', '18', '19', '4', '4', '9, 'sub': 2-14', '2-14', '2', '1', '2', '1', '1-3', '1', '2', '2', '2', '1-3', '2', '3', '3', '1-6', '1-6', '2', '4', '4', '2', '5', '5', '1-3', '1-3', '1-3', '1', '2', '6', '6', '1-3', '1-3', '2', '7', '2', '7', '1-3', '2-9', '2-14, 'Ris a Caryl group (the Caryl group is substituted with —V(wherein —Vis —(CH)mMNRR(wherein Mis —(C═O)— or —(SO)—, mis an integer of 0, 1 or 2, Ris a hydrogen atom or a Calkyl group, and when m=0, Ris —(CH)mOR(wherein mis an integer of 1 or 2, and Ris a hydrogen atom, a Calkyl group or —(CH)mT (wherein mis an integer of 1 or 2, and T is a hydroxyl group, a Calkoxy group or a Calkyl group)), —(CH)mNRR(wherein mis an integer of 1 or 2, and each of Rand Ris independently a hydrogen atom or —(CH)mQ (wherein mis an integer of 1 or 2, and Q is a hydroxy group, a Calkoxy group, —NRR(wherein each of Rand Ris independently a hydrogen atom or a Calkyl group)), or Rand Rmean, together with each other as —NRR, a substituent represented by the formula (II) or the formula (III) (wherein Ris a hydrogen atom, a Calkyl group or an amino-protecting group)), and when m=1 or 2, Ris any of those mentioned above or a hydrogen atom)), —V(wherein —Vis —(CH)mNRR(wherein mis an integer of 1 or 2, and each of Rand Ris independently a hydrogen ...

Подробнее
19-09-2013 дата публикации

THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS

Номер: US20130245283A1
Принадлежит: ALLERGAN, INC.

A compound comprising a prodrug of a prostaglandin EPagonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. 2. The compound according to wherein R is isopropyl.3. The compound according to wherein R is ethylene glycol.6. The compound according to wherein R is isopropyl.7. The compound according to wherein R is ethylene glycol.11. The compound according to wherein R is isopropyl.12. The compound according to wherein R is ethylene glycol. This application is a continuation application of U.S. application Ser. No. 12/834,174 filed Jul. 12, 2010 which is a continuation of U.S. application Ser. No. 11/688,147 filed Mar. 19, 2007, which is based on, and claims priority under 35 U.S.C. §120 to U.S. Provisional Patent Application No. 60/744,234, filed on Apr. 4, 2006, and all of which are incorporated by reference herein in their entirety.1. Field of the InventionThis invention relates to therapeutically active compounds and their delivery and use. Particularly, this invention relates to the delivery and use of prostaglandin EPagonists.2. Description of Related ArtProstaglandins can be described as derivatives of prostanoic acid which have the following structural formula:Various types of prostaglandins are known, depending on the structure and substituents carried on the alicyclic ring of the prostanoic acid skeleton. Further classification is based on the number of unsaturated bonds in the side chain indicated by numerical subscripts after the generic type of prostaglandin [e.g. prostaglandin E(PGE1), prostaglandin E(PGE)], and on the configuration of the substituents on the alicyclic ring indicated by α or β [e.g. prostaglandin F (PGF)].Certain 10,10-dimethyl prostaglandins are known. These are described in documents such as the following:United States Patent Application Publication 2004/0142969 A1, expressly incorporated by reference herein, discloses compounds according to the formula belowthe application discloses the identity ...

Подробнее
26-09-2013 дата публикации

Compounds And Methods For Treating Candidiasis And Aspergillus Infections

Номер: US20130252964A1
Принадлежит: POLYMEDIX, INC.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a or species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an infection. 2. The method of wherein each X is S.3. The method of wherein each Ris claim 1 , independently claim 1 , —CH claim 1 , —(CH)—NH claim 1 , —(CH)—NH—C(═NH)NH claim 1 , or —(CH)—NH—C(═O)—R claim 1 , where each n is claim 1 , independently claim 1 , 1 or 2 claim 1 , and each Ris claim 1 , independently claim 1 , H or methyl.49-. (canceled)10. The method of wherein each Ris CF.11. The method of wherein each Vis H and each Vis claim 1 , independently claim 1 , —N—C(═O)—R claim 1 , where each Ris claim 1 , independently claim 1 , —(CH)—NHor —(CH)—NH—C(═NH)NH claim 1 , where each n is claim 1 , independently claim 1 , 1 to 4.1218-. (canceled)19. The method of wherein each Vis H and each Vis —S—R claim 1 , where each Ris —(CH)—NHwhere each n is 2.20. The method of wherein each Ris H claim 1 , —S—(CH)—NH claim 1 , or —S—(CH)—NH—C(═NH)NH claim 1 , where each m is claim 1 , independently claim 1 , 1 to 4.2123-. (canceled)24. The method of wherein:each X is S;{'sup': '1', 'sub': 2', 'n', '2', '2', 'n', '2, 'each Ris, independently, —(CH)—NHor —(CH)—NH—C(═NH)NH, where each n is, independently, 1 to 4;'}{'sup': '2', 'sub': 3', '3', '3, 'each Ris, independently, halo, CF, or C(CH); and'}{'sup': 1', '2', '5', '5, 'sub': 2', 'n', '2, 'each Vis H and each Vis, independently, —S—R, where each Ris, independently, —(CH)—NH, where each n is, independently, 1 to 4.'}2532-. (canceled)3553-. (canceled)5576-. (canceled)7880-. (canceled)82122-. (canceled)124159-. (canceled)161179-. (canceled)181198-. (canceled)200218-. (canceled)220237-. (canceled)239243-. (canceled)245252-. (canceled) The present disclosure was supported by funds from the U.S. Government (NIH/NIDCR Grant No. 2R44DE018371-02) and the U.S. Government may therefore have certain rights in the ...

Подробнее
26-09-2013 дата публикации

NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE

Номер: US20130253022A1
Принадлежит:

Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, heavy metal toxicity and any neurodegenerative disease involving glutamate toxicity. 2. The compound according to wherein R is phenyl claim 1 , 2-fluorophenyl claim 1 , 3-fluorophenyl claim 1 , 4-fluorophenyl claim 1 , 2 claim 1 ,4-difluorophenyl claim 1 , 2 claim 1 ,5-difluorophenyl claim 1 , 2 claim 1 ,6-difluorophenyl claim 1 , 2-chlorophenyl claim 1 , 2-bromophenyl claim 1 , 2-trifluoromethylphenyl claim 1 , 3-trifluoromethylphenyl claim 1 , 2 claim 1 ,6-dichlorophenyl claim 1 , 2 claim 1 ,4-dichlorophenyl claim 1 , 2-methylphenyl claim 1 , 2-ethylphenyl claim 1 , 2-methoxyphenyl claim 1 , 2-chloro-6-fluorophenyl claim 1 , 2-chloro-4-fluorophenyl claim 1 , 2-fluoro-6-methoxyphenyl claim 1 , 4-fluoro-2-methoxyphenyl claim 1 , 2-chloro-6-methoxyphenyl claim 1 , benzo[b]thiophen-3-yl claim 1 , or benzo[d]isoxazol-3-yl.3. The compound according to wherein Ris methyl or hydrogen.4. The compound according to wherein Ris fluorine.5. The compound according to that is:2,2-Difluoro-2-phenyl-ethyl-1-sulfamide;2,2-Difluoro-2-(2-fluorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(3-fluorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(4-fluorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2,6-difluorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2,4-difluorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2,5-difluorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2-chlorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2-trifluoromethylphenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(3-trifluoromethylphenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2,6-dichlorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2,4-dichlorophenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2-methylphenyl)ethyl-1-sulfamide;2,2-Difluoro-2-(2-methoxyphenyl)ethyl-1-sulfamide;2,2- ...

Подробнее
03-10-2013 дата публикации

Highly Active Multidentate Catalysts for Efficient Alkyne Metathesis

Номер: US20130261295A1

The invention relates to highly active and selective catalysts for alkyne metathesis. In one aspect, the invention includes a multidentate organic ligand wherein one substrate-binding site of the metal center is blocked. In another aspect, the invention includes N-quaternized or silane-based multidentate organic ligands, capable of binding to metals. In yet another aspect, the invention includes N-quaternized or silane-based multidentate catalysts. The catalysts of the invention show high robustness, strong resistance to small alkyne polymerization and significantly enhanced catalytic activity compared to their corresponding non-quaternized or non-silane-based multidentate catalyst analogues. 2. The compound of claim 1 , wherein Ris N and each G is independently substituted with at least one electron-withdrawing substituent.3. The compound of claim 1 , where Ris selected from the group consisting of N claim 1 ,NH(A) claim 1 , NR(A) claim 1 , B claim 1 , P claim 1 , CH claim 1 , CR claim 1 , SiR and a 1 claim 1 ,3 claim 1 ,5-trivalent phenyl moiety claim 1 , wherein R is optionally substituted alkyl or aryl claim 1 , and A is an anion.8. The compound of claim 7 , wherein M is a transition metal.9. The compound of claim 8 , wherein M is selected from the group consisting of Mo claim 8 , W claim 8 , Re and Ta.10. The compound of claim 7 , wherein Ris N and each G is independently substituted with at least one electron-withdrawing substituent.11. The compound of claim 7 , where Ris selected from the group consisting of N claim 7 ,NH(A) claim 7 , NR(A) claim 7 , B claim 7 , P claim 7 , CH claim 7 , CR claim 7 , SiR and a 1 claim 7 ,3 claim 7 ,5-trivalent phenyl moiety claim 7 , wherein R is optionally substituted alkyl or aryl claim 7 , and A is an anion.12. The compound of claim 7 , wherein G is phenyl claim 7 , naphthyl or anthracenyl.14. The compound of claim 13 , wherein Ris NH(A) or N(R)(A) claim 13 , R is optionally substituted alkyl or aryl claim 13 , and A is an ...

Подробнее
10-10-2013 дата публикации

SYNTHESIS OF ACIDIC SILICA TO UPGRADE HEAVY FEEDS

Номер: US20130264245A1
Принадлежит:

A method and a product made by treating a sulfur-containing hydrocarbon heavy feed, e.g., heavy crude asphaltene reduction is disclosed herein. The method comprises the steps of: mixing the sulfur-containing hydrocarbon heavy feed with a hydrogen donor solvent and an acidified silica to form a mixture and oxidizing the sulfur in the mixture at a temperature between 50° C. and 210° C., wherein the oxidation lowers the amount sulfur in the sulfur-containing hydrocarbon heavy feed by at least 90%. 1. A method of extracting sulfur from an oxidized hydrocarbon feed comprising the steps of:mixing a solution comprising a sulfur containing oxidized hydrocarbon feed, an acidified silica, a hydrogen donor solvent, any unreacted materials and reaction by-products with one or more polar organic solvents;allowing the sulfur containing oxidized hydrocarbon feed to migrate to the polar organic solvent phase; andremoving the one or more polar organic solvents by evaporation to recover the sulfur.2. The method of claim 1 , wherein the oxidized hydrocarbon feed comprises asphaltenes claim 1 , tar sands claim 1 , bitumens claim 1 , heavy petroleum or mixtures thereof.3. The method of claim 1 , wherein the hydrogen donor solvent is selected from the group consisting of hydrogen claim 1 , natural petroleum claim 1 , bases claim 1 , alcohols claim 1 , decahydronaphthalene claim 1 , and tetrahydronaphthalene.4. The method of claim 1 , wherein acidified silica has a pH range from 0 to 2.5. The method of claim 1 , wherein the acidified silica comprises an amorphous silica or a silica gel.6. The method of claim 1 , wherein the polar organic solvent is selected from the group consisting of ethanol claim 1 , methanol claim 1 , n-propanol claim 1 , isopropanol claim 1 , n-butanol claim 1 , formic acid claim 1 , acetic acid claim 1 , 1 claim 1 ,4-dioxane claim 1 , THF claim 1 , dichloromethane claim 1 , acetone claim 1 , acetonitrile claim 1 , DMF claim 1 , DMSO claim 1 , and any combinations ...

Подробнее
10-10-2013 дата публикации

GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

Номер: US20130267706A1
Принадлежит:

The invention provides compounds of formula I: 121-. (canceled)2329-. (canceled) This application claims the benefit of U.S. Provisional Application No. 60/967,914, filed on Sep. 7, 2007; the disclosure of which is incorporated herein by reference in its entirety.1. Field of the InventionThe present invention relates to guanidine-containing compounds having muscarinic receptor antagonist or anticholinergic activity. The invention also relates to pharmaceutical compositions comprising these compounds, processes for preparing them and methods of use to treat pulmonary disorders.2. State of the ArtPulmonary or respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma, afflict many millions of people worldwide and such disorders are a leading cause of morbidity and mortality.Muscarinic receptor antagonists are known to provide bronchoprotective effects and therefore, such compounds are useful for treating respiratory disorders, such as COPD and asthma. When used to treat such disorders, muscarinic receptor antagonists are typically administered by inhalation. However, even when administered by inhalation, a significant amount of the muscarinic receptor antagonist is often absorbed into the systemic circulation resulting in systemic side effects, such as dry mouth, mydriasis and cardiovascular side effects.Additionally, many inhaled muscarinic receptor antagonists have a relatively short duration of action requiring that they be administered several times per day. Such a multiple-daily dosing regime is not only inconvenient but also creates a significant risk of inadequate treatment due to patient non-compliance with the required frequent dosing schedule.Accordingly, a need exists for new muscarinic receptor antagonists. In particular, a need exists for muscarinic receptor antagonists having high potency, reduced systemic side effects when administered by inhalation, and a long duration of action thereby allowing for once-daily or even once- ...

Подробнее
17-10-2013 дата публикации

Process for the Preparation of (3E, 7E)-Homofarnesol

Номер: US20130273619A1
Принадлежит: BASF SE

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol). 112-. (canceled)14. The process according to claim 13 , wherein a cyclopropylphosphonium salt is used for the Wittig olefination according to stage a).16. The process according to claim 15 , wherein Zis a halide.17. The process according to claim 15 , wherein Z is bromide.18. The process according to claim 15 , wherein the compound of the formula V is prepared by reacting a) bromobutyrolactone with triphenylphosphine and then thermally decarboxylating the reaction product claim 15 , or b) reacting 1 claim 15 ,3-dibromopropane with triphenylphosphine and then cyclizing the reaction product.19. The process according to claim 13 , in which the ring-opening in stage b) takes place in the presence of a Lewis acid or Brönstedt acid/protonic acid and a nucleophile.20. The process according to claim 17 , wherein the ring opening takes place essentially stereoselectively claim 17 , in particular E-selectively (with respect to R).21. The process according to claim 13 , wherein claim 13 , in stage c) claim 13 , the compound of the general formula IV is converted to a compound of the general formula I by claim 13 , when X is OR′ claim 13 , carrying out an ester cleavage claim 13 , or when X is halogen claim 13 , converting the halide to an ester and then cleaving this ester.22. The process according to claim 13 , wherein claim 13 , in stage c) claim 13 , the compound of the general formula IV is converted to a compound of the general formula I by claim 13 , when X is OR′ claim 13 , carrying out an ester cleavage claim 13 , or when X is halogen claim 13 , converting the halide to a formate ester claim 13 , and then cleaving this ester.27. A process for preparing enantiomerically pure ambrox or a stereoisomer mixture of ...

Подробнее
17-10-2013 дата публикации

SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS

Номер: US20130274249A1
Принадлежит:

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. 134-. (canceled)36. The method of claim 35 , wherein said cognitive or psychiatric disorder is caused by a dysfunction of a voltage-gated sodium channel.37. The method of claim 35 , wherein said cognitive or psychiatric disorder is caused by a dysfunction of a voltage-gated calcium channel.38. The method of claim 35 , wherein said patient is sensitive to unwanted side effects of MAO inhibitory effects.39. The method of claim 35 , wherein said disorder is a cognitive and/or psychiatric disorder selected from the group consisting of Mild Cognitive Impairment (MCI) claim 35 , depression claim 35 , bipolar disorder claim 35 , mania claim 35 , schizophrenia claim 35 , psychosis claim 35 , anxiety and addiction.40. The method of claim 35 , wherein the compound is administered with at least one other therapeutic agent.41. The method of claim 40 , wherein the at least one other therapeutic agent is an antipsychotic selected from the group consisting of haloperidol claim 40 , risperidone and clozapine.42. The method of claim 41 , wherein the antipsychotic is haloperidol or risperidone.43. The method of claim 35 , wherein the effective amount of the compound administered to the patient in need thereof (i) does not exhibit any MAO-inhibitory activity or (ii) exhibits a reduced MAO-inhibitory activity relative to safinamide or ralfinamide.44. The method of claim 35 , wherein the compound is 2-[2-(3-butoxyphenyl)-ethylamino]-N claim 35 ,N-dimethylacetamide or a pharmaceutically ...

Подробнее
17-10-2013 дата публикации

Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof

Номер: US20130274470A1
Принадлежит:

Provided herein are triazolium carbine catalysts useful for asymmetric hydration, fluorination, and deuteration, and processes for their preparation. Also provided are synthetic reactions in which these catalysts are used, in particular, in stereoselective formation of carbon-chlorine, carbon-hydrogen, carbon-fluorine, and carbon-deuterium bonds. 2. The compound of wherein the counter ion X is selected from the group consisting of BF claim 1 , Cl claim 1 , PF claim 1 , BPh claim 1 , and RBF.3. A composition comprising a compound of formula (I) according to claim 1 , a proton donor claim 1 , and a base.5. The method of claim 4 , wherein the aldehyde is an enal.6. The method of claim 4 , wherein the aldehyde is a α claim 4 ,α-dichloro aldehyde or an α-chloro α-fluoro aldehyde.8. The method of wherein claim 4 , the asymmetric hydration results in an enantiomeric excess of the respective α-deuterio carboxylic acid claim 4 , α-deuterio-α-chloro carboxylic acid or α-deuterio-α-fluoro carboxylic acid.9. The method of further comprising contacting the aldehyde with an additive selected from phase transfer reagents claim 4 , salts claim 4 , and brine.11. The method of claim 10 , wherein the aldehyde is an enal.12. The method of claim 10 , wherein the aldehyde is a α claim 10 ,α-dichloro aldehyde or an α-chloro α-fluoro aldehyde.14. The method of claim 10 , wherein the drug analog is an α-fluoroenal and the asymmetric hydration forms an α-fluoro carboxylic acid.15. The method of claim 10 , wherein the asymmetric hydration results in an enantiomeric excess of the respective drug analog.17. The method of claim 16 , wherein the aldehyde is an enal.18. The method of claim 16 , wherein the aldehyde is a α claim 16 ,α-dichloro aldehyde or an α-chloro α-fluoro aldehyde.20. The method of claim 4 , wherein the base is selected from the group consisting of KCO claim 4 , NaHCO claim 4 , KHPO claim 4 , NaCO claim 4 , KPO claim 4 , EtN claim 4 , DIPEA claim 4 , DBU claim 4 , DBN claim 4 , ...

Подробнее
24-10-2013 дата публикации

ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES

Номер: US20130281453A1
Принадлежит: The Scripps Research Institute

Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified through library versus library screening can be used for treatment of malconditions associated with the specific serine hydrolase KIAA1363 (also known as AADACL1). A library of inhibitors of KIAA1363 was prepared and candidate compounds were identified as a potent inhibitors having submicromolar ICvalues. An exemplary compound of the invention was shown to be an effective inhibitor of prostate cancer pathogenesis. Other inhibitory compounds of the invention comprising fluorophore groups are shown to be effective in spatial and temporal localization of the serine hydrolase in cells and tissues. 1. (canceled)3. (canceled)4. (canceled)7. The compound of wherein Ris a substituted or unsubstituted benzyl claim 6 , phenethyl claim 6 , phenylpropyl claim 6 , benzhydrylalkyl claim 6 , naphthylalkyl claim 6 , thienylalkyl claim 6 , indolylalkyl claim 6 , or morpholinylalkyl group.8. The compound of wherein Ris a group of formula FL-W— claim 2 , wherein W is a linker bonding a fluorophore FL to the carbamate nitrogen atom claim 2 , W comprising a bond claim 2 , an alkylene group claim 2 , an oxygen atom claim 2 , an amino group claim 2 , a carbonyl group claim 2 , an alkylenecarbonyl group claim 2 , a carboxamido group claim 2 , or an alkylene carboxamido group.11. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable excipient.12. A method of inhibiting a serine hydrolase KIAA1363 claim 2 , comprising contacting the hydrolase in vitro or in vivo with an effective amount or concentration of a compound of .13. A method of treating a malcondition associated with a serine hydrolase KIAA1363 claim 2 , comprising administering to a patient afflicted with the malcondition an ...

Подробнее
31-10-2013 дата публикации

IDO Inhibitors

Номер: US20130289083A1
Принадлежит:

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. 211-. (canceled)12. The pharmaceutical composition of claim 1 , wherein Ris hydrogen.1319-. (canceled)20. A pharmaceutical composition comprising a pharmaceutically acceptable excipient claim 1 , diluent claim 1 , or carrier and a compound selected fromO-((5-chlorobenzo[b]thiophen-3-yl)methyl)hydroxylamine,O-(benzo[d]thiazol-2-ylmethyl)hydroxylamine,O-(benzofuran-2-ylmethyl)hydroxylamine,and a pharmaceutically acceptable salt thereof2120. A method for treating indoleamine 2 claim 1 ,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof claim 1 , comprising ...

Подробнее
31-10-2013 дата публикации

PROCESS FOR OBTAINING DRONEDARONE

Номер: US20130289287A1
Принадлежит: LABORATORIOS LESVI, S.L.

The present invention provides a process for obtaining dronedarone or salts thereof characterized in that in an organic phase comprising one or more non-polar solvents, 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butyl-benzofuran is reacted with methane sulfonyl chloride without the addition of a base. The invention also provides a process for obtaining intermediates of dronedarone environmentally friendly and industrially viable. 2. The process according to claim 1 , wherein the non-polar solvent is toluene.3. The process according to claim 1 , wherein the acceptable salt of dronedarone is a hydrochloride salt.4. The process according to claim 3 , wherein dronedarone is reacted with trimethylsilyl chloride in the presence of water.6. The process according to wherein the strong base is selected from potassium hydroxide claim 5 , barium hydroxide claim 5 , cesium hydroxide claim 5 , sodium hydroxide claim 5 , strontium hydroxide claim 5 , calcium hydroxide and lithium hydroxide.7. The process according to wherein the catalyst used in step b) is a metallic catalyst selected from platinum- or palladium-based catalyst.8. The process according to including formation of an acid addition salt of compound I.9. The process according to wherein the acid addition salt of compound I is formed with oxalic acid.10. The process according to including a neutralization step. The present invention is directed to an improved process for obtaining dronedarone.Dronedarone or N-[2-Butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-methanesulfonamide is a class III antiarrhythmic, chemically related to amiodarone developed by Sanofi-Aventis. It prolongs the duration of action potentials and has antiadrenergic and coronary vasodilatory effects. It is launched in the US as dronedarone hydrochloride under the tradename MULTAQ. This drug is indicated in adult stable patients with history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to ...

Подробнее
14-11-2013 дата публикации

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES

Номер: US20130302422A1
Принадлежит:

Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof. 2. The method according to claim 1 , wherein X is O.5. The method according to claim 1 , wherein each of Rand Ris respectively hydrogen.9. The composition according to claim 1 , wherein the compound of Formula 1 or Formula 2 is contained in a crystalline structure.10. The method according to claim 1 , wherein the compound of Formula 1 is contained in an amorphous structure.11. The composition according to claim 1 , wherein the compound of Formula 1 or Formula 2 is formulated into the form of a fine particle.12. The composition according to claim 11 , wherein the formulation for form of a fine particle is carried out by using the particle micronization method selected from the group consisting of mechanical milling claim 11 , spray drying claim 11 , precipitation method claim 11 , homogenization claim 11 , and supercritical micronization.13. The composition according to claim 12 , wherein the formulation is carried out by using jet milling as a mechanical milling and/or spray drying.14. The composition according to claim 11 , wherein the particle size of fine particles is 5 nm to 500 μm.15. The method according to claim 1 , wherein the pharmaceutical composition is prepared into an intestine-targeted formulation.16. The method according to claim 15 , wherein the intestine-targeted formulation comprises a pH sensitive polymer.17. The method according to claim 15 , wherein the intestine-targeted formulation comprises a biodegradable polymer which is decomposable by an intestine-specific bacterial enzyme.18. The method according to claim 15 , wherein the intestine-targeted formulation comprises a biodegradable matrix ...

Подробнее
14-11-2013 дата публикации

Ire1alpha endonuclease specific inhibitor with cytotoxic activity

Номер: US20130303599A1
Принадлежит: Leland Stanford Junior University

Activation of the adaptive Ire1-XBP1 pathway has been identified in many solid tumors and hematological malignancies, including multiple myeloma (MM). What is disclosed is STF-083010, a novel small molecule inhibitor of Ire1. STF-083010 inhibited Ire1 endonuclease activity, without affecting its kinase activity, after ER stress both in vitro and in vivo. Treatment with STF-083010 showed significant anti-myeloma activity in model human MM xenografts. Similarly, STF-083010 was preferentially toxic to freshly isolated human CD138(+) MM cells when compared to other similarly isolated cell populations. The identification of this novel Ire1 inhibitor supports the hypothesis that the Ire1-XBP1 axis is a promising target for anti-cancer therapy, especially in the context of multiple myeloma.

Подробнее
21-11-2013 дата публикации

Alpha, beta-unsaturated imines

Номер: US20130310254A1
Принадлежит: Bayer Intellectual Property GmbH

The present application relates to novel alpha, beta-unsaturated imines, to processes for their preparation, to their use for controlling animal pests including arthropods and in particular insects and to their use in the control of vectors. 2. The compound according to claim 1 , where Arepresents —C(R claim 1 ,R)—.3. The compound according to claim 1 , where Arepresents a —C(R claim 1 ,R)— group and where{'sup': 2', '3, 'said C(R,R)— group forms a double bond with the adjacent B position, or'}{'sup': 2', '3', '1', '2', '1', '2, 'sub': 'n', 'said C(R,R)— group is a bridging group which, together with a further bridging group and any B groups, located between these bridging groups, of the C(═C(W,X-Q)-C(═N-Q)-A-[B]-Aring and a corresponding bridge U forms an unsubstituted or substituted cyclic system, or'}{'sup': 2', '3, 'this said C(R,R)— group carries a substituent V.'}4. The compound according to claim 1 , where Ais part of a cyclic system.5. The compound according to claim 1 , where Ais part of a carbocyclic system comprising 6 ring atoms or part of a 5- or 6-membered heterocyclic system.6. The compound according to claim 5 , where Ais part of an aromatic system comprising 6 ring atoms or part of a 5- or 6-membered heteroaromatic system.7. The compound according to claim 1 , where n is 2.11. An insecticidal composition claim 1 , wherein said insecticidal composition comprises at least one compound according to claim 1 , and an extender and/or surfactant.12. A method for protecting transgenic and/or conventional seed and a plant generated therefrom against attack by pests claim 1 , comprising treating the seed with at least one compound according to .13. A compound according claim 1 , capable of being used for controlling pests.14. A compound according to claim 1 , capable of being used for controlling vectors.15. A seed in which a compound according to claim 1 , has been applied to said seed as a constituent of a casing and/or as a further layer and/or further ...

Подробнее
21-11-2013 дата публикации

Process for the Preparation of N-Monosubstituted beta-Amino Alcohols

Номер: US20130310574A1
Принадлежит: Lonza AG

A process is disclosed for the preparation of a compound of formula 18.-. (canceled)1011.-. (canceled)1320.-. (canceled) The invention relates to a process for the preparation of N-monosubstituted β-amino alcohols of formulaand/or an addition salt of a proton acid via direct synthesis of N-monosubstituted β-keto amines of formulaand/or an addition salt of a proton acid.N-Monosubstituted β-amino alcohols of formula I like (S)-(−)-3-N-methylamino-1-(2-thienyl)-1-propanol (LY293628) are useful key intermediates and building blocks for the preparation of pharmaceutically active compounds like (S)-(+)-methyl-[3-(1-naphthyloxy)-3-(2-thienyl)-propyl]-amine ((S)-duloxetine) (Liu, H. et al., 12 (2000) 26-29), a potential neuro-active compound which strongly inhibits the serotonine and norephedrine uptake (Deeter, J. et al., 31 (1990) 7101-7104).In the following the terms “amine” or “amines” include their corresponding addition salts of proton acids.Direct preparation of N-monosubstituted β-keto amines of formula II establishes an alternative and economically advantageous source for industrial production of N-monosubstituted β-amino alcohols of formula I.Compounds of formula II were first synthesized in 1922 by reacting ketones with formaldehyde and primary or secondary alkylamines in the presence of hydrochloric acid (Mannich, C. et al., 55 (1922) 356-365). In said reactions with primary alkylamines formation of hydrochlorides of tertiary β-keto amines of formulaprevails over formation of hydrochlorides of secondary β-keto amines of formula II. These findings were supported by Blicke et al. (64 (1942) 451-454) and Becker et al. (-11 (1969) 38-41).According to Mannich et al. steam destillation of tertiary β-keto amines of formula III results in formation of secondary β-keto amines of formula II in fairly satisfactory yields, accompanied by vinyl compounds and other by-products.In spite of the loss of more than 50% of the starting compounds and due to lack of alternative ...

Подробнее
05-12-2013 дата публикации

USE OF GLUTARIC ACID DERIVATIVES OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ANTI-ARRHYTHMIC AGENTS

Номер: US20130324540A1

The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents. 15-. (canceled) The instant invention relates to medicine and to the use of glutaric acid derivatives, in particular N-acyl amino acid derivatives and pharmaceutically acceptable salts thereof as anti-arrhythmic agents for correction of disorders in the rhythm of cardiac activity.It is well-known that at the present time propranolol (anaprilin, obzidan) and amiodaron (cordaron) are anti-arrhythmic agents that are widely used in clinical practice.Their main defects are insufficient effectiveness and low therapeutic diapason, which is manifested by the high frequency of cardial and extracardial side effects. [Mashkovsky M. D. Medicaments. Manual for doctors. Publication 15. Publishing House Novaya Volna. 2005. pages 390-392, 264-266].The analog of the claimed compounds that is closest in respect to action is the N-succinyl-D,L-tryptophane dipotassium salt exhibiting anti-ischemic, cardiotonic and anti-arrhythmic action upon research [Bulletin of experimental biology and medicine. 1998. vol. 125. No. 5. pages 544-547].A defect of the known compound is the low anti-arrhythmic activity upon parenteral administration, and also insufficient diapason of therapeutic action.In view of the aforesaid, what is real is the search for new anti-arrhythmic agents that are capable of manifesting high anti-arrhythmic activity upon parenteral administration and are highly effective upon treatment of disorders of cardiac rhythm.The anti-allergic and hypolipidemic action of N-acyl derivatives of biogenic amines, for example, glutaryl histamine, is described in the publication of international application WO 99/01103.Histidine and tryptophane N-acyl derivatives of amino acids are disclosed in the publication of international application WO 2006/135280, wherein the use thereof as anti-allergic and lipid-controlling agents is ...

Подробнее
12-12-2013 дата публикации

COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

Номер: US20130328021A1
Принадлежит: Samsung Display Co., Ltd.

Embodiments of the present disclosure are directed to a compound represented by Formula 1, and to organic light-emitting diodes including the compound. 2. The compound of claim 1 , wherein:{'sub': 1', '2', '1', '30', '5', '30', '3', '30', '6', '30, 'Rand Rare each independently a halogen group, a cyano group, a substituted or unsubstituted C-Calkyl group, a substituted or unsubstituted C-Caryl group, a substituted or unsubstituted C-Cheteroaryl group, or a substituted or unsubstituted C-Ccondensed polycyclic group;'}{'sub': 3', '5', '30', '3', '30', '6', '30, 'Ris hydrogen, deuterium, a halogen group, a cyano group, a substituted or unsubstituted C-Caryl group, a substituted or unsubstituted C-Cheteroaryl group, or a substituted or unsubstituted C-Ccondensed polycyclic group;'}{'sub': 6', '10', '2', '11, 'A is a linking group such as a substituted or unsubstituted C-Carylene group, a substituted or unsubstituted C-Cheteroarylene group, or a linking group in which at least two arylene groups and/or heteroarylene groups are linked; and'}{'sub': 1', '2', '5', '30', '3', '30', '6', '30, 'Arand Arare each independently a substituted or unsubstituted C-Caryl group, a substituted or unsubstituted C-Cheteroaryl group, or a substituted or unsubstituted C-Ccondensed polycyclic group.'}7. The compound of claim 1 , wherein Rand Rcombine to form a ring.9. An organic light-emitting diode comprising:a first electrode;a second electrode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an organic layer between the first electrode and the second electrode, wherein the organic layer comprises the compound according to .'}10. The organic light-emitting diode of claim 9 , wherein the organic layer is a hole injection layer claim 9 , a hole transport layer claim 9 , or a functional layer having both hole injection and hole transport abilities.11. The organic light-emitting diode of claim 9 , wherein the organic layer is a hole transport layer or a hole injection layer.12. The ...

Подробнее
12-12-2013 дата публикации

COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS

Номер: US20130331411A1
Принадлежит:

The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof. 12-. (canceled)46-. (canceled)821-. (canceled)26. The method of claim 22 , wherein the patient is in need of inhibition of platelet activation.27. The method of claim 22 , wherein the patient is in need of inhibition of thrombus formation.28. The method of claim 22 , wherein the PAR1 disease is particular proliferative diseases of endothelial cells claim 22 , fibroblasts claim 22 , nephrocytes claim 22 , osteosarcoma cells claim 22 , muscle cells claim 22 , cancer cells and/or glia cells.2930-. (canceled)31. The method of claim 22 , wherein said PAR1 mediated disease is selected from acute Myocardial Infarction claim 22 , stable angina claim 22 , unstable angina claim 22 , aortocoronary bypass surgery claim 22 , acute occlusion following coronary angioplasty and or stent placement claim 22 , transient Ischemic attacks claim 22 , cerebrovascular disease claim 22 , peripheral vascular disease claim 22 , placental insufficiency claim 22 , prosthetic heart valves claim 22 , atrial fibrillation claim 22 , anticoagulation of tubing.32. (canceled)33. The method of claim 22 , wherein said disease or disorder is selected from acute myocardial infarction claim 22 , stable angina claim 22 , unstable angina claim 22 , transient ischemic attack claim 22 , cerebrovascular disease claim 22 , peripheral vascular disease claim 22 , placental insufficiency claim 22 , thrombosis subsequent to or associated with a surgical procedure claim 22 , thrombosis associated with atrial fibrillation claim 22 , and inflammation.3436-. (canceled)37. The method of claim 22 , wherein Cyl and Gare aromatic groups and Gis an alkyl group.38. The method of claim 22 , wherein each Gand Gis a group containing at least two carbons independently selected from aliphatic claim 22 , substituted ...

Подробнее
12-12-2013 дата публикации

AMINOTETRALINE DERIVATIVES

Номер: US20130331429A1
Принадлежит:

The present application relates generally to amino tetraline derivative compounds and methods of use, specifically, embodiments including compounds of formula (I) described herein, pharmaceutically acceptable salts and solvates. More specifically, this application relates to amino tetraline derivative compounds and uses of such compounds producing medicaments for the treatment of various disease and conditions including movement disorders and disorders of the central nervous system. 2. The method of claim 1 , wherein the movement disorder is an L-DOPA associated dyskinesia.3. The method of wherein R of the compound of formula I is OR1 claim 1 , wherein R1 is methyl claim 1 , hydrogen or a group —C(═O)R2 claim 1 , wherein R2 is (C1-C6)alkyl or (C1-C6)alkyloxy.4. The method of wherein Cy of the compound of formula I is a 5 or 6 membered aromatic or heteroaromatic ring which is selected from the group of phenyl claim 1 , thienyl claim 1 , furanyl claim 1 , imidazolyl claim 1 , 1 claim 1 ,2 claim 1 ,3-triazolyl claim 1 , 1 claim 1 ,2 claim 1 ,4-triazolyl claim 1 , pyrazolyl claim 1 , pyridyl claim 1 , pyrimidyl claim 1 , and unsubstituted or substituted with one or two groups R4.5. The method according to wherein the compound of formula I administered to a recipient is selected fromN-(8-Hydroxytetralin-2-yl)-N-propyl-N-[2-(2-thienyl)ethyl]amine,(R)—N-(8-Hydroxytetralin-2-yl)-N-propyl-N-[2-(2-thienyl)ethyl]amine,(S)—N-(8-Hydroxytetralin-2-yl)-N-propyl-N-[2-(2-thienyl)ethyl]amine,N-(8-Methoxytetralin-2-yl)-N-propyl-N-[2-(2-thienyl)ethyl]amine,(R)—N-(8-Methoxytetralin-2-yl)-N-propyl-N-[2-(2-thienyl)ethyl]amine,(S)—N-(8-Methoxytetralin-2-yl)-N-propyl-N-[2-(2-thienyl)ethyl]amine,N-[2-(4-Hydroxyphenyl)ethyl]-N-(8-hydroxytetralin-2-yl)-N-propylamine,N-[2-(4-Methoxyphenyl)ethyl]-N-(8-methoxytetralin-2-yl)-N-propylamine,N-[2-(2,5-Dimethylphenyl)ethyl]-N-(8-hydroxytetralin-2-yl)-N-propylamine,N-[2-(2,5-Dimethylphenyl)ethyl]-N-(8-methoxytetralin-2-yl)-N-propylamine,N-[2-(1- ...

Подробнее
26-12-2013 дата публикации

PROCESS FOR THE PREPARATION OF ROTIGOTINE

Номер: US20130345283A1
Принадлежит: FIDIA FARMACEUTICI S.p.A.

A process for the preparation of Rotigotine (1) 1. Rotigotine hydrochloride crystalline Form A characterized by the following IR , DSC and XRD spectra:{'sup': '−1', 'IR (cm): 3074; 2946; 2621; 1732; 1589; 1464; 1367; 1275; 1083; 1025; 963; 850; 771; 729'}DSC: onset temperature: 108.8° C.; peak temperature: 123.0° C.X-ray spectrum (2θ): 7.1; 8.4; 9.8; 10.0; 13.2; 14.5; 14.8; 17.1; 17.8; 18.0; 18.8; 20.7; 22.9; 23.5; 25.4.2. Rotigotine hydrochloride crystalline Form B , characterized by the following IR , DSC and XRD spectra:{'sup': '−1', 'IR (cm): 3058; 2966; 2633; 1588; 1464; 1436; 1347; 1275; 1207; 1161; 1086; 1049; 1027; 85; 950; 898; 850; 805; 772; 709.'}DSC: onset temperature: 134.5° C.; peak temperature: 146.0° C.X-ray spectrum (2θ): 6.9; 9.2; 9.3; 13.3; 14.8; 15.0; 17.6; 17.8; 19.2; 19.6; 20.8; 21.9; 23.2; 24.2; 24.6; 25.0.3. Pharmaceutical compositions containing Rotigotine hydrochloride Form A according to in admixture with pharmaceutically acceptable excipients and/or carriers.4. Pharmaceutical compositions containing Rotigotine hydrochloride Form B according to in admixture with pharmaceutically acceptable excipients and/or carriers. This application is a divisional application of U.S. Ser. No. 13/120,682 filed on Jun. 13, 2011 which a U.S. national stage of PCT/IB2009/006934 filed on Sep. 24, 2009 which claims priority to and the benefit of Italian Application No. MI2008A1713 filed on Sep. 26, 2008, the contents of which are incorporated herein by reference in their entirety.The present invention relates to 5,6,7,8-tetrahydro-6-S-[N-propyl-2-(2-thienyl)-N-ethyl]amino-1-naphthalenol, commonly known as Rotigotine (1), a medicament used in the therapy of the early stages of idiopathic Parkinson's disease, usually in the form of its hydrochloride salt.The preparation and therapeutical uses of Rotigotine were first disclosed in U.S. Pat. No. 4,564,628 and U.S. Pat. No. 4,885,308. The product currently pharmaceutically used is the S enantiomeric form or its ...

Подробнее
26-12-2013 дата публикации

Carboxylation of poly-/oligothiophenes

Номер: US20130345440A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a process for carboxylation of poly/oligothiophenes using CO 2 .

Подробнее
02-01-2014 дата публикации

Process for producing thiophene compound and intermediate thereof

Номер: US20140005413A2
Принадлежит: Nissan Chemical Corp

To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. A 2-aryl acetate compound represented by the formula (1): wherein R 1 is an aryl group or the like, R 4 is a C 1-3 alkyl group or the like, and X is a leaving group, is reacted with a thioacetic acid compound to form a thioacetyl compound (3), the thioacetyl compound (3) is reacted with a vinyl ketone compound to form a γ-ketosulfide compound (5), which is cyclized under basic conditions to form a dihydrothiophene compound (6), and the dihydrothiophene compound (6) is oxidized by using an oxidizing agent to produce a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound (7).

Подробнее
02-01-2014 дата публикации

PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE

Номер: US20140005414A1
Принадлежит: SCI Pharmtech, Inc.

The present invention provides a process for preparing duloxetine hydrochloride with higher yield and lower cost. 1. A process for preparing (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride , comprising steps of:dissolving (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine in an organic solvent to form a mixture, wherein the organic solvent is at least one of C3-8 ketones; andadding anhydrous hydrochloride to the mixture, wherein the anhydrous hydrochloride is formed by an acid chloride and an alcohol.2. The process according to claim 1 , wherein the organic solvent is acetone.3. The process according to claim 1 , wherein the acid chloride is represented by a formula of RCOCl claim 1 , and wherein Ris selected from H claim 1 , Calkyl group claim 1 , thionyl chloride (SOCl) and phosphoryl chloride (POCl).4. The process according to claim 1 , wherein the alcohol is represented by a formula of ROH claim 1 , in which Ris Calkyl.5. The process according to claim 1 , wherein the mixture is heated at 50° C.6. The process according to claim 1 , wherein the anhydrous hydrochloride is added to the mixture until a pH value is in a range from 5.5 to 7.5.7. The process according to claim 1 , wherein the anhydrous hydrochloride is added to the mixture and then heated at a temperature from 40 to 60° C.8. The process according to claim 7 , wherein the anhydrous hydrochloride is added to the mixture and then heated at 50° C.10. The process of claim 9 , wherein R is Calkyl.11. The process of claim 10 , wherein R is methyl.12. The process of claim 9 , wherein the halonaphthalene is 1-fluoronaphthalene.13. The process of claim 9 , wherein Ris tert-butyl.14. The process of claim 9 , wherein the reaction of the (S)-(−)-3-methylamino-1-(2-thienyl)propan-1-ol with halonaphthalene is carried out in presence of excess halonaphthalene claim 9 , and wherein DMSO is used in an amount ranging from one to ten times the amount of (S)-(−)-3-methylamino-142-thienyl) ...

Подробнее
09-01-2014 дата публикации

Process for preparing chiral amino acids

Номер: US20140012005A1
Принадлежит: Diverchim SA

The present invention relates to a process for preparing chiral amino acids with excellent enantiomeric excesses.

Подробнее
16-01-2014 дата публикации

USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS

Номер: US20140018549A1
Принадлежит: NPS PHARMACEUTICALS, INC.

Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias, wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R; Ris chosen from: alkyl or haloalkyl; Ris chosen from: H, C(O)R, C(O)OR, SO2Ror C(O)NRR; R, Rand Rare independently chosen from: H or alkyl; Rand Rare independently chosen from: H or alkyl; and Ris chosen from: OH, CN, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, C(O)R, C(O)OR, SO2Ror C(O)NRR. 120-. (canceled)23. The pharmaceutical composition of claim 21 , wherein:{'sup': 2', '6', '6', '6, 'sub': '2', 'Ris chosen from: H, C(O)R, C(O)OR, or SOR;'}{'sup': 3', '4', '5, 'R, Rand Rare each H;'}{'sup': '6', 'Ris alkyl; and'}{'sup': '8', 'Ris chosen from: halo or alkyl.'}25. The pharmaceutical composition of claim 24 , wherein:{'sup': '1', 'sub': '2', 'Ris chosen from: methyl or CHF; and'}{'sup': '6', 'Ris chosen from: methyl or tert-butyl.'}26. The pharmaceutical composition of claim 24 , wherein;{'sup': '8', 'A is aryl, optionally substituted with up to 5 independently-selected groups R;'}{'sup': 2', '6, 'Ris C(O)R; and'}{'sup': '8', 'Ris halo.'}27. The pharmaceutical composition of claim 26 , wherein;{'sup': '1', 'Ris haloalkyl; and'}{'sup': '6', 'Ris methyl.'}30. The pharmaceutical composition of claim 21 , wherein the anxiety disorder is chosen from: generalized anxiety disorder (GAD) claim 21 , panic attack claim 21 , post traumatic stress disorder (PTSD) claim 21 , obsessive compulsive disorder (OCD) or social phobias. The present disclosure relates the use serine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their usefulness in the treatment of anxiety disorders.Anxiety is broadly defined as a state of unwarranted or inappropriate worry often accompanied by ...

Подробнее
16-01-2014 дата публикации

REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING AMINE INTERMEDIARY COMPOUND

Номер: US20140018554A1
Автор: FRIESZ Antal, HUSZAR Csaba
Принадлежит: SANOFI

The invention relates to a novel process for preparation of drohedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that a compound of formula (II) is reacted in the presence of a reductive agent with butyraldehyde and/or butanoic acid, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some hovel intermediary compounds and the preparation thereof. 2. The process according to claim , wherein triacetoxyborohydride is applied as reductive agent when butyraldehyde is used as butylating reagent and sodium borohydride is applied as reductive agent when butanoic acid is used as butylating reagent.3. The process according to claim , wherein the amount of triacetoxyborohydride or sodium borohydride is 1 to 5 equivalents , the amount of butyraldehyde is 2 to 4 equivalents when using triacetoxyborohydride and 0 to 2 equivalents when using sodium borohydride , where the equivalents are calculated for compounds of formula (II).9. The compound according to claim 8 , wherein the Pg amino protecting group is an A-CO— group claim 8 , where A is alkyl claim 8 , alkoxy claim 8 , aryl or aryloxy group. This invention relates to a novel process for the preparation of dronedarone and pharmaceutically acceptable salts thereof, to novel intermediary compounds used in this process and their preparation.Dronedarone is a known drug for the treatment of arrhythmia and has the chemical name of N-[2-n-butyl-3-[4-[3-(di-n-butylamino)propoxy]benzoyl]benzofuran-5-yl]methanesulfonamide [see also formula (I) below]. There are some known processes for the preparation of dronedarone as follows:In EP 0471609 the following scheme is disclosed for the preparation of dronedaroneThe above mentioned patent description discloses some new intermediary compounds, too.In WO 02/48078 the following scheme is disclosed for the preparation of dronedaroneThe novelty of the process is based ...

Подробнее
23-01-2014 дата публикации

INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF

Номер: US20140024608A1
Принадлежит: METHYLGENE INC.

The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. 134.-. (canceled)37. A composition comprising a compound of or a pharmaceutically acceptable salt thereof.38. A composition comprising a compound of or a pharmaceutically acceptable salt thereof. This application claims the benefit of priority of U.S. Application No. 60/870,768, filed Dec. 19, 2006.1. Field of the InventionThis invention relates to the inhibition of histone deacetylase. More particularly, the invention relates to compounds and prodrugs thereof that inhibit, histone deacetylase enzymatic activity. The invention also relates to methods of inhibiting histone deacetylase enzymatic activity.2. Summary of the Related ArtIn eukaryotic cells, nuclear DNA associates with histones to form a compact complex called chromatin. The histones constitute a family of basic proteins which are generally highly conserved across eukaryotic species. The core histones, termed H2A, HB, H3, and H4, associate to form a protein core. DNA winds around this protein core, with the basic amino acids of the histones interacting with the negatively charged phosphate groups of the DNA. Approximately 146 base pairs of DNA wrap around a histone core to make up a nucleosome particle, the repeating structural motif of chromatin.Csordas, 286: 23-38 (1990) teaches that histones are subject to posttranslational acetylation of the e-amino groups of N-terminal lysine residues, a reaction that is catalyzed by histone acetyl transferase (HAT1). Acetylation neutralizes the positive charge of the lysine side chain, and is thought to impact chromatin structure. Indeed, Taunton et al., 272: 408-411 (1996), teaches that access of transcription factors to chromatin templates is enhanced by histone ...

Подробнее
23-01-2014 дата публикации

PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS

Номер: US20140024645A1
Принадлежит: HIGH POINT PHARMACEUTICALS, LLC

Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same. 2. The method of claim 1 , wherein Xis morpholin-4-ylmethyl.3. A method of treating type I diabetes claim 1 , type II diabetes claim 1 , impaired glucose tolerance claim 1 , insulin resistance claim 1 , or obesity claim 1 , the method comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of:(E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid; andZ)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid; ora pharmaceutically acceptable salt thereof.4. The method of claim 3 , wherein the compound is (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.5. The method of claim 3 , wherein the compound is (Z)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.7. The method of claim 6 , wherein Xis morpholin-4-ylmethyl.8. The method of claim 6 , wherein the compound is (E)-[4-[3-(4-Chlorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methylphenyl]-propionic acid or a pharmaceutically acceptable salt thereof.9. The method of claim 6 , wherein the compound is (Z)-[4-[3-(4-Chlorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methylphenyl]-propionic acid or a pharmaceutically acceptable salt thereof.10. A method of treating type I diabetes claim 6 , type II diabetes claim 6 , impaired glucose tolerance claim 6 , insulin resistance claim 6 , or obesity claim 6 , the method comprising administering to ...

Подробнее
30-01-2014 дата публикации

CYCLIC SULFONIUM SALT, PROCESS FOR PRODUCTION OF SAME, AND alpha-GLUCOSIDASE INHIBITOR COMPRISING SAME

Номер: US20140031394A1
Принадлежит:

Provided is a novel cyclic sulfonium salt compound which is useful for the prevention or treatment of diabetes and the like. The present invention relates to a novel cyclic sulfonium salt compound represented by general formula (I) or (II), an isomer or solvate of the compound, or a pharmaceutically acceptable salt of the compound or the isomer or solvate. The present invention also relates to an α-glucosidase inhibitor, a pharmaceutical composition for preventing or treating diabetes, and an anti-diabetes food, each of which comprises the compound represented by general formula (I) or (II) and the like. 3. The cyclic sulfonium salt compound or the isomer or the solvate thereof or the pharmaceutically acceptable salt thereof as claimed in or , wherein Ris hydrogen atom or —CHOH or —(CH)—CHOH).4. The cyclic sulfonium salt compound or the isomer or the solvate thereof or the pharmaceutically acceptable salt thereof as claimed in or , wherein Ris a C-Calkyl group or benzyl group , o- , m- or p-halobenzyl group , o- , m- or p-nitrobenzyl group , o- , m- or p-methylbenzyl group , o- , m- or p-trifluoromethylbenzyl group , hydroxymethylbenzyl group , naphthylmethyl group or pyridylmethyl group.5. The cyclic sulfonium salt compound or the isomer or the solvate thereof or the pharmaceutically acceptable salt thereof as claimed in or , wherein X is Cl or BF.6. The cyclic sulfonium salt compound or the isomer or the solvate thereof or the pharmaceutically acceptable salt thereof as claimed in or , wherein Ris hydrogen atom or —CHOH or —(CH)—CHOH) , and Ris a C-Calkyl group or benzyl group , o- , m- or p-halobenzyl group , o- , m- or p-nitrobenzyl group , o- , m- or p-methylbenzyl group , o- , m- or p-trifluoromethylbenzyl group , hydroxymethylbenzyl group , naphthylmethyl group or pyridylmethyl group.7. A medical composition for inhibition of α-glucosidase containing a cyclic sulfonium salt compound or the isomer or the solvate thereof or the pharmaceutically acceptable salt ...

Подробнее
30-01-2014 дата публикации

TRPM8 RECEPTOR ANTAGONISTS

Номер: US20140031398A1
Принадлежит:

Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: 2. The compounds according to claim 1 , wherein claim 1 , independently one from the other:R is selected from H, Br and CN;{'sub': 1', '3, 'X is selected from F, Cl and C-Calkyl;'}{'sub': 2', '2, 'Y is selected from —O—, CH, NH and SO;'}{'sub': '3', 'R1 and R2, independently one from the other, are selected from H, F and CH;'}{'sub': '3', 'R3 and R4, independently one from the other, are selected from H and CH;'}{'sup': '+', 'sub': '3', 'Z is selected from NR6 and R6R7N, where R6 and R7, independently one from the other, are selected from H and CH; and'}{'sub': '3', 'R5 is selected from H and CH.'}3. The compounds according to claim 1 , wherein claim 1 , independently one from the other claim 1 ,R is selected from H and CN;X is selected from F and Cl;{'sub': 2', '2, 'Y is selected from CH, O and SO;'}{'sup': '+', 'sub': 3', '2, 'Z is selected from NH and N(CH);'}R5 is H; and{'sub': '3', 'Het is substituted with at least one substituent selected from F, Cl and CH.'}4. The compounds according to claim 1 , wherein Het is 5-substituted pyrrol-2-yl claim 1 , 5-substituted N-methylpyrrol-2-yl claim 1 , or 5-substituted thiophen-2-yl or 5-substituted fur-2-yl.5. The compounds according to claim 1 , selected from the group consisting of:2-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanaminium chloride (1);2-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]ethanaminium chloride (2);N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]ethanaminium (3);2-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]ethanaminium (4);2-[(1-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)ethanaminium (5);2-[(1-chloronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethyl)ethanaminium (6);2-[(1-chloronaphthalen-2-yl)oxy]-N-[(1-methyl-1H-pyrrol-2-yl)methyl]ethanaminium (7);1-[(1-chloronaphthalen-2-yl) ...

Подробнее
30-01-2014 дата публикации

PROCESS FOR PREPARING (S)-3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOL

Номер: US20140031564A1
Принадлежит: Saltigo GmbH

The present invention relates to a method for preparing (S)-3-N-methylamino-1-(2-thienyl)-1-propanol and salts thereof. 2. Method according to claim 1 , characterized in that arene is mesitylene claim 1 , cumene claim 1 , p-cumene claim 1 , o-cymene claim 1 , m-cymene or benzene.3. Method according to or claim 1 , characterized in that R′ is methyl claim 1 , ethyl claim 1 , n- claim 1 , isopropyl claim 1 , n- claim 1 , sec- claim 1 , tert-butyl or n- claim 1 , sec-pentyl or fluorine or chlorine.4. Method according to one or more of to claim 1 , characterized in that n =0 or 1 claim 1 , preferably n=0.5. Method according to one or more of to claim 1 , characterized in that the amine is a tertiary amine claim 1 , preferably triethylamine.6. Method according to one or more of to claim 1 , characterized in that the method is carried out in the presence of a solvent selected from the group consisting of amides claim 1 , nitriles or alcohols or mixtures of these solvents.7. Method according to one or more of to claim 1 , characterized in that the molar ratio of formic acid to tertiary amine is from 3:1 to 0.8:1.8. Method according to one or more of to claim 1 , characterized in that the method is carried out at a temperature of 30° C. to 60° C.9. Method according to one or more of to claim 1 , characterized in that the molar amount of ruthenium used claim 1 , based on the amount of 3-N-alkylamino-1-(2-thienyl)-1-propanone or salts thereof claim 1 , is from 0.05 to 1 mol %.10. Method according to one or more of to claim 1 , characterized in that the salt of the compound 3-N-alkylamino-1-(2-thienyl)-1-propanone used is the methanesulphonate or the hydrochloride.11. Method according to one or more of to claim 1 , characterized in that (S)-3-N-methylamino-1-(2-thienyl)-1-propanol is prepared with an enantiomeric purity of more than 90%. The present invention relates to a method for preparing (S)-3-N-methylamino-1-(2-thienyl)-1-propanol and salts thereof.(S)-3-N-methylamino-1 ...

Подробнее
06-02-2014 дата публикации

METHOD FOR PRODUCING N-SUBSTITUTED AMINE COMPOUNDS THROUGH CATALYZED ALKYLATION

Номер: US20140039181A1

The invention relates to a method for producing a N-substituted amine compound by catalyzed alkylation. The method uses amine and alcohol or two kinds of amines as the reaction materials, employs composite metal oxides catalyst at a reaction temperature of 80-180° C. to catalyze the reaction for 6-36 hours, so as to produce the N-substituted amine compound. The reaction condition of the method of the invention is relatively moderate, using a catalyst made of cheap non-noble metals, which is non-caustic and easy to be separated and reused. The reaction does not need any medium and has relatively high conversion rate and selectivity. 2. The method of claim 1 , wherein the molar ratio of Cu to Ni is from 10:1 to 1:10 claim 1 , and the molar ratio of Cu to Fe is from 10:1 to 1:10 in CuO—NiO—FeO.3. The method of claim 1 , wherein the molar ratio of Ni to Fe in NiO—FeOis from 10:1 to 1:10.4. The method of claim 1 , wherein the molar ratio of Cu to Fe in CuO—FeOis from 10:1 to 1:10.5. The method of claim 1 , wherein the molar ratio of Cu to Ni in CuO—NiO is from 10:1 to 1:10.6. (canceled)7. The method of claim 1 , wherein the mass ratio between the composite metal oxide catalyst and the amine is from 0.01:1 to 1.2:1.8. The method of claim 1 , wherein the composite metal oxide catalyst is produced by the following steps:{'sub': 3', '2', '3', '2', '3', '3', '3', '3, '1) adding an aqueous solution of any two or three nitrates selected from Cu(NO), Ni(NO), and Fe(NO), and an aqueous Al(NO)solution, to an aqueous alkali metal oxide or hydroxide solution, aqueous ammonia, or aqueous carbamide solution which functions as a precipitator to coprecipitate;'}2) after step 1), providing a crude catalyst by washing, drying in the air, calcining, and reducing in hydrogen gas;{'sub': 3', '4', '3', '4', '3', '4, '3) using an aqueous alkali metal hydroxide solution to remove any alumina in the crude catalyst obtained in steps 1) and 2) to provide a composite metal oxides catalyst CuO—NiO— ...

Подробнее
06-02-2014 дата публикации

SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS

Номер: US20140039183A1
Принадлежит:

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated. 161-. (canceled)62. A method for the synthesis of a compound comprising an indane moiety having a chiral carbon in the five-membered ring of the indane moiety where the compound is enantiomerically enriched with respect to the chiral carbon , the method comprising the steps of(i) providing a compound comprising an indane moiety where the ring carbon of the five-membered ring of the indane moiety where chiral substitution is desired is oxo substituted at such carbon, and wherein a carbon of the phenyl ring is halo substituted;{'sub': 2', '2-6', '3-8, '(ii) reacting such compound with a chiral reagent selected from the group consisting of a Corey Bakshita Shibata-oxazaborolidine and a chiral sulfinamide of the form RS(═O)NHwhere R is selected from the group consisting of t-butyl, branched Calkyl and Ccycloalkyl; and'}(iii) forming the chiral center at the indane moiety carbon previously bound to the oxo group by either reacting such compound with a suitable reducing agent along with the chiral reagent in step (ii) or reacting the result of the reaction of such compound with a suitable reducing agent.63. The method of wherein the chiral reagent is the Corey Bakshita Shibata-oxazaborolidine.64. The method of wherein the chiral reagent is (R)-(−)-(2)-methyl-CBS-oxazaborolidine or (S)-(−)-(2)-methyl-CBS-oxazaborolidine.67. The method of wherein the protecting agent is TBSCl.69. The method of wherein the chiral reagent is RS(═O)NHand the compound comprising an ...

Подробнее
20-02-2014 дата публикации

HETEROCYCLIC RESORCINOL DERIVATIVES, PREPARATION OF SAME AND COSMETIC USES THEREOF

Номер: US20140050683A1
Принадлежит: PIERRE FABRE DERMO-COSMETIQUE

The invention relates to a compound of general formula (I) 2. The compound in accordance with claim 1 , characterized in that Ris a methyl group.3. The compound in accordance with claim 1 , characterized in that Ris a heteroaromatic single-ring claim 1 , preferably with 5 or 6 members.4. The compound in accordance with claim 1 , characterized in that Ris selected from the group consisting of a pyridine claim 1 , thiophene and thiazole heterocycle.5. The compound in accordance with claim 1 , characterized in that Ris a methyl group and Ris selected from the group consisting of 3-pyridyl claim 1 , 4-pyridyl claim 1 , 2-furyl claim 1 , 3-furyl claim 1 , 2-thiophenyl claim 1 , 3-thiophenyl claim 1 , and 2-thiazolyl.6. The compound in accordance with claim 1 , characterized in that it is selected from one of the following compounds:4-(1-(pyridin-2-yl)ethyl)benzene-1,3-diol;4-(1-(pyridin-3-yl)ethyl)benzene-1,3-diol;4-(1-(pyridin-4-yl)ethyl)benzene-1,3-diol;4-(1-(thiophene-2-yl)ethyl)benzene-1,3-diol;4-(1-(thiophene-3-yl)ethyl)benzene-1,3-diol;4-(1-(thiazol-2-yl)ethyl)benzene-1,3-diol;4-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethyl)benzene-1,3-diol;4-(1-(1-methyl-1H-indol-2-yl)ethyl)benzene-1,3-diol;4-(1-(benzo[1)]thiophene-2-yl)ethyl)benzene-1,3-diol;4-(1-(thiophene-2-yl)butyl)benzene-1,3-diol;4-(3-methyl-1-(thiophene-2-yl)butyl)benzene-1,3-diol.7. A compound as defined in accordance with claim 1 , for use as a cosmetic active ingredient.8. A compound as defined in accordance with claim 1 , for use as a drug.9. A compound as defined in accordance with claim 1 , for use as a depigmenting active ingredient.10. A compound as defined in accordance with claim 1 , for use as an antioxidant active ingredient.11. A pharmaceutical or cosmetic composition claim 1 , characterized in that it includes as active ingredient at least one compound of formula (I) such as defined in accordance with in combination with a pharmaceutically or cosmetically acceptable excipient.13. The cosmetic ...

Подробнее
20-02-2014 дата публикации

Lipophilic Curcumin Analogs And Methods Of Inhibiting HIV-1, Treating Latent HIV In The Brain, And Preventing HIV-Mediated Cognitive Decline And HIV Dementia

Номер: US20140051742A1
Принадлежит:

Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally. 2. The method according to claim 1 , wherein the pharmaceutical composition is intranasally administered.3. The method according to claim 1 , wherein the pharmaceutical composition further comprises an antiviral agent other than at least one compound of formulas (I) to (VIII).4. The method according to claim 3 , wherein the antiviral agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors claim 3 , nonnucleoside reverse transcriptase inhibitors claim 3 , protease inhibitors claim 3 , integrase inhibitors claim 3 , fusion inhibitors claim 3 , chemokine receptor antagonists claim 3 , and combinations thereof.5. The method according to claim 1 , wherein the analog is dispersed into a pharmaceutically acceptable oil.8. A compound having any of formulas (II) to (VIII) as defined in .9. A pharmaceutical composition comprising at least one compound having any of formulas (II) through (VIII) as defined in .10. The pharmaceutical composition according to claim 9 , further comprising a pharmaceutically acceptable excipient claim 9 , diluent claim 9 , and/or carrier.11. The pharmaceutical composition according to claim 9 , ...

Подробнее
20-02-2014 дата публикации

SYNTHESIS OF AN ANTIVIRAL COMPOUND

Номер: US20140051866A1
Принадлежит: Gilead Sciences, Inc.

The present disclosure provides a processes for the preparation of a compound of Formula I: 7. The process of claim 5 , wherein the N-arylation reaction conditions comprise a catalyst.8. The process of claim 7 , wherein the catalyst is a palladium claim 7 , platinum claim 7 , or copper based catalyst.9. The process of claim 8 , wherein the catalyst is selected from the group consisting of tris(dibenzylideneacetone)dipalladium(0) claim 8 , copper(I) chloride claim 8 , copper(II) chloride claim 8 , copper(I) bromide claim 8 , copper(II) bromide claim 8 , copper(I) acetate claim 8 , copper(II) acetate claim 8 , copper(II) acetylacetonate claim 8 , copper(I) trifluoromethanesulfonate claim 8 , copper(II) trifluoromethanesulfonate claim 8 , copper(I) thiophene-2-carboxylate claim 8 , and copper(I) iodide.10. The process of claim 7 , wherein the N-arylation reaction conditions further comprise a ligand.11. The process of claim 10 , wherein the ligand is selected from the group consisting of 5-(di-tert-butylphosphino)-1′ claim 10 ,3′ claim 10 ,5′-triphenyl-1′H-[1 claim 10 ,4′]bipyrazole claim 10 , 2-(di-tert-butyl-phosphino)-1-phenyl-1H-pyrrole claim 10 , 2-(di-tert-butylphosphino)-1-(2-methoxyphenyl)-1H-pyrrole claim 10 , acetylacetone claim 10 , acetylcyclohexanone claim 10 , isobutyrylcyclohexanone claim 10 , N claim 10 ,N-dimethylcyclohexane-1 claim 10 ,2-diamine claim 10 , L-proline claim 10 , BINAP claim 10 , and N claim 10 ,N-diethylsalicylamide.12. The process of claim 7 , wherein the N-arylation reaction conditions further comprise a base.13. The process of claim 12 , wherein the base is selected from the group consisting of potassium hydroxide claim 12 , sodium hydroxide claim 12 , sodium tert-amylate claim 12 , cesium carbonate claim 12 , cesium hydroxide claim 12 , potassium phosphate tribasic claim 12 , sodium tertbutoxide claim 12 , sodium methoxide claim 12 , and sodium ethoxide.14. The process of claim 4 , wherein the acylation reaction conditions comprise ...

Подробнее
27-02-2014 дата публикации

BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS

Номер: US20140057953A1
Принадлежит:

The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 2 (l7beta-HSD2) inhibitors of formula (I), their production and use, notably for the treatment and prophylaxis of sex steroid deficient diseases like osteoporosis in men and women. 5. The compound according to claim 1 , wherein the variables claim 1 , if present claim 1 , have the following meaning:{'sub': '2', 'R1 and R3 are independently selected from H, —OH, alkoxy, alkyl, —N(R8), halogen, haloalkyl and phenyl;'}{'sub': 2', '2', '2', '2', '2', '2', '2', '1-6', '1-6, 'R2, R4, R6 and R7 are independently selected from H, —OR8, —COR8, —COOR8, —CONHR8, —OCOR8, —SON(R8), —N(R8), —NHCOR8, —NHSOR8, halogen, —CHN(R8), —CHOR8, aryl optionally substituted with up to three R8, Calkyl optionally substituted with up to three R8 and halo Calkyl;'}R5 is lower alkyl;{'sub': 1-6', '1-6', '2, 'R8 is selected from H, Calkyl optionally substituted with up to three R9, halogen, halo Calkyl, —OH, lower alkoxy, —NH, and 5- or 6-membered aromatic or heteroaromatic ring optionally substituted with up to three R9;'}{'sub': 1-4', '2, 'R9 is selected from —OH, alkoxy, halogen, haloalkyl, Calkyl, —NHand phenyl;'}X, Y and P are independently selected from CH, N, N(H) and S; and/orn is 0 or 1.8. The compound according to claim 1 , which is selected from the group consisting of3′-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-4-carboxamide (1),3′-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-4-carboxamide (2),N-(3-methoxybenzyl)-N,3′-dimethylbiphenyl-4-carboxamide (3),N-(3-hydroxybenzyl)-N,3′-dimethylbiphenyl-4-carboxamide (4),4′-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-3-carboxamide (5),4′-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide (6),3′-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-3-carboxamide (7,3′-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide (8),4′-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide (9),4′-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-3- ...

Подробнее
27-02-2014 дата публикации

Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase

Номер: US20140057957A1
Автор: Sun Xicheng
Принадлежит: N30 PHARMACEUTICALS, INC.

The present invention is directed to novel thiophene inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. 4. The method of wherein ArRRis selected from the group consisting of 4-methoxyphenyl claim 2 , 4-chloro-2-methoxyphenyl claim 2 , 4-hydroxyphenyl claim 2 , 4-carbamoylphenyl claim 2 , and 4-bromophenyl.5. The method of wherein Ris selected from the group consisting of hydrogen claim 1 , methyl claim 1 , and methoxy.9. The method of wherein ArRRis selected from the group consisting of 4-methoxyphenyl claim 7 , 4-chloro-2-methoxyphenyl claim 7 , 4-hydroxyphenyl claim 7 , 4-carbamoylphenyl claim 7 , and 4-bromophenyl.10. The method of wherein Ris selected from the group consisting of hydrogen claim 6 , methyl claim 6 , and methoxy.11. The method of selected from the group consisting of3-(3-(4-carbamoyl-2-methylphenyl)-4-(4-methoxyphenyl)thiophen-2-yl)propanoic acid;3-(3-(4-carbamoylphenyl)-4-(4-chloro-2-methoxyphenyl)thiophen-2-yl)propanoic acid;3-(3-(4-chloro-2-methoxyphenyl)-4-(4-hydroxyphenyl)thiophen-2-yl)propanoic acid;3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)propanoic acid;3-(4-(4-chloro-2-methoxyphenyl)-3-(4-(methylsulfonamido)phenyl)thiophen-2-yl)propanoic acid;3-(4-(4-carbamoylphenyl)-3-(4-(2-methyl-1H-imidazol-1-yl)phenyl)thiophen-2-yl)propanoic acid;3-(3-(4-carbamoyl-2-methylphenyl)-4-(4-(2-methyl-1H-imidazol-1-yl)phenyl)thiophen-2-yl)propanoic acid;3-(3-(4-carbamoylphenyl)-4-(4-(2-methyl-1H-imidazol-1-yl)phenyl)thiophen-2-yl)propanoic acid;3-(4-(4-(2-methyl-1H-imidazol-1-yl)phenyl)-3-(2-methyl-4-(methylsulfonamido)phenyl)thiophen-2-yl)propanoic acid;3-(4-(4-chloro-2-methoxyphenyl)-3-(2-methyl-4-(methylsulfonamido)phenyl)thiophen-2-yl)propanoic acid;3-(4′-(4-carbamoyl-2-methylphenyl)-5-(2-methyl-1H-imidazol-1-yl)-2,3′-bithiophen-5′-yl)propanoic acid;3-(5-(2-methyl-1H-imidazol-1-yl)-4′-(2-methyl-4-(methylsulfonamido)phenyl)-2,3 ...

Подробнее
06-03-2014 дата публикации

Thiophene-2-carboximidamide Based Selective Neuronal Nitric Oxide Inhibitors

Номер: US20140066635A1
Принадлежит: Northwestern University

Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability. 1. A compound of a formulawherein L is a divalent CHCHmoiety with a meta-relationship to each said thiophene-2-carboximidamide moiety of said compound; or a salt thereof. This application claims priority benefit from application Ser. No. 61/695,187 filed Aug. 30, 2012, application Ser. No. 61/698,249 filed Sep. 7, 2012 and application Ser. No. 61/774,926 filed Mar. 8, 2013—each of which is incorporated herein by reference in its entirety.This invention was made with government support under grant number GM049725 awarded by the National Institutes of Health. The government has certain rights in the invention.Neuronal nitric oxide synthase (nNOS) catalyzes the oxidation of L-arginine to L-citrulline in the central nervous system, generating nitric oxide (NO), a critical neurotransmitter. Significant research has implicated the overexpression of nNOS—and overproduction of NO—in various neurological diseases, including Parkinson's, Alzheimer's, and Huntington's diseases, as well as neuronal damage due to stroke, cerebral palsy and migraine headaches. Inhibiting endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) is, however, undesirable, because these isozymes are responsible for maintaining crucial body function. Thus, selective inhibition of nNOS over its closely related isoforms, eNOS and iNOS, has provided a promising strategy in the development of therapeutics for the treatment of neurodegenerative diseases. However, while certain compounds have exhibited good potency and high selectivity, they often suffer from poor bioavailability. As a result, there remains an on-going search in the art for effective bioavailable NOS inhibitors to realize the therapeutic potential of such compounds.In light of the foregoing, it is an object of the present invention to provide compounds ...

Подробнее
20-03-2014 дата публикации

Inhibitors of Histone Deacetylase

Номер: US20140080800A1
Принадлежит:

The present invention relates to compounds of formula (I): 5. The compound of or a pharmaceutically acceptable salt claim 4 , hydrate claim 4 , solvate claim 4 , or prodrug thereof claim 4 , wherein Ris selected from phenyl claim 4 , 2-pyridinyl claim 4 , 3-pyridinyl claim 4 , 4-pyridinyl claim 4 , 2-pyrimidinyl claim 4 , 4-pyrimidinyl claim 4 , 5-pyrimidinyl claim 4 , 2-pyrazinyl claim 4 , oxazolyl claim 4 , thiazolyl claim 4 , and isoxazolyl.12. A pharmaceutical composition comprising an effective amount of a compound of or a pharmaceutically acceptable salt claim 1 , hydrate claim 1 , solvate claim 1 , or prodrug thereof and a pharmaceutical carrier claim 1 , diluent claim 1 , or excipient.13. A method of treating claim 1 , alleviating claim 1 , and/or preventing a condition wherein said condition is associated with histone deacetylase activity in a subject comprising administering to the subject in need thereof an effective amount of a compound of or a pharmaceutically acceptable salt claim 1 , hydrate claim 1 , solvate or prodrug thereof.14. The method of claim 13 , wherein the condition is selected from a neurological disorder claim 13 , memory loss or impairment claim 13 , cognitive function disorder or impairment claim 13 , extinction learning disorder claim 13 , fungal disease or infection claim 13 , inflammatory disease claim 13 , hematological disease claim 13 , and neoplastic disease.15. The method of claim 14 , wherein the condition is selected from:a cognitive function disorder or impairment associated with Alzheimer's disease, Huntington's disease, seizure induced memory loss, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, Fragile X, Lewy body dementia, vascular dementia, ADHD, dyslexia, bipolar disorder and social, cognitive and learning disorders associated with autism, traumatic head injury, or attention deficit disorder, anxiety disorder, conditioned fear response, panic disorder, obsessive compulsive disorder, posttraumatic stress ...

Подробнее
20-03-2014 дата публикации

PROCESS FOR PREPARATION OF DRONEDARONE BY MESYLATION

Номер: US20140081035A1
Автор: FRIESZ Antal, HUSZAR Csaba
Принадлежит: SANOFI

The invention relates to a novel process for preparation of N-[2-n-butyl-3-[4-[3-(di-n-butylamino)-propoxy]-benzoyl]-benzofuran-5-yl]methanesulfonamide (I) and pharmaceutical acceptable salts thereof, where a salt of (5-amino-2-butyl-1-benzofuran-3-yl) {4-[3-(di-n-butylamino)propoxy]phenyl}methanone of formula (II)—where A is a mono- or dibasic acid forming an acid addition salt with the compound of formula (II), n is 1 if A is dibasic acid and n is 1 or 2 if A is a monobasic acid—is reacted with a mesylating reagent in a heterogen reaction, if desired, in the presence of a phase transfer catalyst. The invention also relates to the novel salts of compound of formula (II), for the preparation thereof and their use in the preparation of dronedarone. 2. The process according to claim 1 , wherein the acid A is selected from the group consisting of hydrogen chloride claim 1 , hydrogen bromide claim 1 , methanesulfonic acid claim 1 , p-toluenesulfonic acid and sulphuric acid.3. The process according to wherein a solvent is applied in which the salt of (5-amino-2-butyl-1-benzofuran-3-yl){4-{3-(di-n-butylamino)propoxy]phenyl}-methanone of forumula (II) is not soluble and the base form of it and acid A are soluble.4. The process according to claim 3 , wherein the solvent is selected from the group consisting of aromatic compounds claim 3 , halogenated aromatic compounds claim 3 , halogenated alkenes or cycloalkanes claim 3 , ethers and ketones and any mixtures thereof.5. The process according to claim 4 , wherein claim 4 , the solvent is selected from the group consisting of toluene claim 4 , xylene claim 4 , chlorobenzene claim 4 , anisole claim 4 , dichloroethane claim 4 , heptane claim 4 , 2-methyl cyclohexane claim 4 , dibutylether claim 4 , methylethyl ketone and any mixtures thereof.6. The process according to claim 1 , wherein the mesylating agent is methanesulfonic anhydride or methanesulfonyl halogenide.7. The process according to claim 1 , wherein the reaction is ...

Подробнее